{\rtf1\adeflang1025\ansi\ansicpg1252\uc1\adeff0\deff0\stshfdbch0\stshfloch0\stshfhich0\stshfbi0\deflang1033\deflangfe1033\themelang1033\themelangfe0\themelangcs0{\fonttbl{\f0\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f1\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604020202020204}Arial;}
{\f34\fbidi \froman\fcharset0\fprq2{\*\panose 02040503050406030204}Cambria Math;}{\f40\fbidi \fswiss\fcharset0\fprq2{\*\panose 020b0604030504040204}Verdana;}{\flomajor\f31500\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbmajor\f31501\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhimajor\f31502\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0302020204030204}Calibri Light;}
{\fbimajor\f31503\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\flominor\f31504\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}
{\fdbminor\f31505\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\fhiminor\f31506\fbidi \fswiss\fcharset0\fprq2{\*\panose 020f0502020204030204}Calibri;}
{\fbiminor\f31507\fbidi \froman\fcharset0\fprq2{\*\panose 02020603050405020304}Times New Roman;}{\f514\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\f515\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\f517\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\f518\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\f519\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\f520\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\f521\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\f522\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\f524\fbidi \fswiss\fcharset238\fprq2 Arial CE;}{\f525\fbidi \fswiss\fcharset204\fprq2 Arial Cyr;}
{\f527\fbidi \fswiss\fcharset161\fprq2 Arial Greek;}{\f528\fbidi \fswiss\fcharset162\fprq2 Arial Tur;}{\f529\fbidi \fswiss\fcharset177\fprq2 Arial (Hebrew);}{\f530\fbidi \fswiss\fcharset178\fprq2 Arial (Arabic);}
{\f531\fbidi \fswiss\fcharset186\fprq2 Arial Baltic;}{\f532\fbidi \fswiss\fcharset163\fprq2 Arial (Vietnamese);}{\f854\fbidi \froman\fcharset238\fprq2 Cambria Math CE;}{\f855\fbidi \froman\fcharset204\fprq2 Cambria Math Cyr;}
{\f857\fbidi \froman\fcharset161\fprq2 Cambria Math Greek;}{\f858\fbidi \froman\fcharset162\fprq2 Cambria Math Tur;}{\f861\fbidi \froman\fcharset186\fprq2 Cambria Math Baltic;}{\f862\fbidi \froman\fcharset163\fprq2 Cambria Math (Vietnamese);}
{\f914\fbidi \fswiss\fcharset238\fprq2 Verdana CE;}{\f915\fbidi \fswiss\fcharset204\fprq2 Verdana Cyr;}{\f917\fbidi \fswiss\fcharset161\fprq2 Verdana Greek;}{\f918\fbidi \fswiss\fcharset162\fprq2 Verdana Tur;}
{\f921\fbidi \fswiss\fcharset186\fprq2 Verdana Baltic;}{\f922\fbidi \fswiss\fcharset163\fprq2 Verdana (Vietnamese);}{\flomajor\f31508\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\flomajor\f31509\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\flomajor\f31511\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flomajor\f31512\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\flomajor\f31513\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\flomajor\f31514\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flomajor\f31515\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\flomajor\f31516\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fdbmajor\f31518\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbmajor\f31519\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fdbmajor\f31521\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fdbmajor\f31522\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbmajor\f31523\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fdbmajor\f31524\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fdbmajor\f31525\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbmajor\f31526\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fhimajor\f31528\fbidi \fswiss\fcharset238\fprq2 Calibri Light CE;}{\fhimajor\f31529\fbidi \fswiss\fcharset204\fprq2 Calibri Light Cyr;}{\fhimajor\f31531\fbidi \fswiss\fcharset161\fprq2 Calibri Light Greek;}
{\fhimajor\f31532\fbidi \fswiss\fcharset162\fprq2 Calibri Light Tur;}{\fhimajor\f31533\fbidi \fswiss\fcharset177\fprq2 Calibri Light (Hebrew);}{\fhimajor\f31534\fbidi \fswiss\fcharset178\fprq2 Calibri Light (Arabic);}
{\fhimajor\f31535\fbidi \fswiss\fcharset186\fprq2 Calibri Light Baltic;}{\fhimajor\f31536\fbidi \fswiss\fcharset163\fprq2 Calibri Light (Vietnamese);}{\fbimajor\f31538\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}
{\fbimajor\f31539\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fbimajor\f31541\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbimajor\f31542\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}
{\fbimajor\f31543\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fbimajor\f31544\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbimajor\f31545\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}
{\fbimajor\f31546\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\flominor\f31548\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\flominor\f31549\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\flominor\f31551\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\flominor\f31552\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\flominor\f31553\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\flominor\f31554\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\flominor\f31555\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\flominor\f31556\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}
{\fdbminor\f31558\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fdbminor\f31559\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}{\fdbminor\f31561\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}
{\fdbminor\f31562\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fdbminor\f31563\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}{\fdbminor\f31564\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}
{\fdbminor\f31565\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fdbminor\f31566\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}{\fhiminor\f31568\fbidi \fswiss\fcharset238\fprq2 Calibri CE;}
{\fhiminor\f31569\fbidi \fswiss\fcharset204\fprq2 Calibri Cyr;}{\fhiminor\f31571\fbidi \fswiss\fcharset161\fprq2 Calibri Greek;}{\fhiminor\f31572\fbidi \fswiss\fcharset162\fprq2 Calibri Tur;}
{\fhiminor\f31575\fbidi \fswiss\fcharset186\fprq2 Calibri Baltic;}{\fbiminor\f31578\fbidi \froman\fcharset238\fprq2 Times New Roman CE;}{\fbiminor\f31579\fbidi \froman\fcharset204\fprq2 Times New Roman Cyr;}
{\fbiminor\f31581\fbidi \froman\fcharset161\fprq2 Times New Roman Greek;}{\fbiminor\f31582\fbidi \froman\fcharset162\fprq2 Times New Roman Tur;}{\fbiminor\f31583\fbidi \froman\fcharset177\fprq2 Times New Roman (Hebrew);}
{\fbiminor\f31584\fbidi \froman\fcharset178\fprq2 Times New Roman (Arabic);}{\fbiminor\f31585\fbidi \froman\fcharset186\fprq2 Times New Roman Baltic;}{\fbiminor\f31586\fbidi \froman\fcharset163\fprq2 Times New Roman (Vietnamese);}}
{\colortbl;\red0\green0\blue0;\red0\green0\blue255;\red0\green255\blue255;\red0\green255\blue0;\red255\green0\blue255;\red255\green0\blue0;\red255\green255\blue0;\red255\green255\blue255;\red0\green0\blue128;\red0\green128\blue128;\red0\green128\blue0;
\red128\green0\blue128;\red128\green0\blue0;\red128\green128\blue0;\red128\green128\blue128;\red192\green192\blue192;\red0\green0\blue0;\red0\green0\blue0;\red255\green255\blue255;\red200\green16\blue46;\red120\green120\blue120;\red102\green102\blue102;}
{\*\defchp }{\*\defpap \ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 }\noqfpromote {\stylesheet{\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext0 \sqformat \spriority0 Normal;}{\*\cs10 \additive \ssemihidden \spriority0 Default Paragraph Font;}{\*
\ts11\tsrowd\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tblind0\tblindtype3\tsvertalt\tsbrdrt\tsbrdrl\tsbrdrb\tsbrdrr\tsbrdrdgl\tsbrdrdgr\tsbrdrh\tsbrdrv 
\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs20\alang1025 \ltrch\fcs0 \fs20\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext11 \ssemihidden \spriority0 Normal Table;}{
\s15\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 \snext15 \sqformat \spriority0 Normal_0;}}
{\*\rsidtbl \rsid2058615\rsid13728027}{\mmathPr\mmathFont34\mbrkBin0\mbrkBinSub0\msmallFrac0\mdispDef1\mlMargin0\mrMargin0\mdefJc1\mwrapRight1\mintLim0\mnaryLim1}{\info{\author Romero, Cesar (Associated)}{\operator Romero, Cesar (Associated)}
{\creatim\yr2020\mo1\dy13\hr11\min35}{\revtim\yr2020\mo1\dy13\hr11\min35}{\version2}{\edmins0}{\nofpages1}{\nofwords9532}{\nofchars54334}{\nofcharsws63739}{\vern2073}}{\*\xmlnstbl {\xmlns1 http://schemas.microsoft.com/office/word/2003/wordml}}
\paperw12240\paperh15840\margl720\margr720\margt720\margb720\gutter0\ltrsect 
\widowctrl\ftnbj\aenddoc\trackmoves0\trackformatting1\donotembedsysfont0\relyonvml0\donotembedlingdata1\grfdocevents0\validatexml1\showplaceholdtext0\ignoremixedcontent0\saveinvalidxml0\showxmlerrors1\noxlattoyen
\expshrtn\noultrlspc\dntblnsbdb\nospaceforul\formshade\horzdoc\dgmargin\dghspace180\dgvspace180\dghorigin600\dgvorigin0\dghshow1\dgvshow1
\jexpand\viewkind5\viewscale100\pgbrdrhead\pgbrdrfoot\splytwnine\ftnlytwnine\htmautsp\nolnhtadjtbl\useltbaln\alntblind\lytcalctblwd\lyttblrtgr\lnbrkrule\nobrkwrptbl\snaptogridincell\allowfieldendsel\wrppunct
\asianbrkrule\nojkernpunct\rsidroot2058615\utinl \fet0{\*\wgrffmtfilter 013f}\ilfomacatclnup0\stylesortmethod0{\*\ftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13728027 \chftnsep 
\par }}{\*\ftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid13728027 \chftnsepc 
\par }}{\*\aftnsep \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid13728027 \chftnsep 
\par }}{\*\aftnsepc \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid13728027 \chftnsepc 
\par }}\ltrpar \sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Contents}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\insrsid13728027 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2058615 {\shp{\*\shpinst\shpleft0\shptop0\shpright10800\shpbottom0\shpfhdr0\shpbxcolumn\shpbxignore\shpbypara\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz1\shplid2052
{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fNoFillHitTest}{\sv 0}}{\sp{\sn lineWidth}{\sv 12700}}
{\sp{\sn dhgt}{\sv 251658240}}{\sp{\sn fEditedWrap}{\sv 0}}{\sp{\sn fBehindDocument}{\sv 0}}{\sp{\sn fIsButton}{\sv 0}}{\sp{\sn fPseudoInline}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxcolumn\dobypara\dodhgt8193
\dpline\dpptx0\dppty0\dpptx10800\dppty0\dpx0\dpy0\dpxsize10800\dpysize0\dplinew20\dplinecor0\dplinecog0\dplinecob0}}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }}{\footerr \ltrpar \ltrrow\trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 \hich\f1 COPYRIGHT \'a9\loch\f1  2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved
\par }\pard \ltrpar\ql \li0\ri0\sl200\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK "https://\hich\af1\dbch\af1\loch\f1 marketintelligence.spglobal.com/" }}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 spglobal.com/marketintelligence}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \cell }\pard \ltrpar\qr \li0\ri0\sl340\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
{\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 PAGE}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\hich\af1\dbch\af1\loch\f1 2}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 
\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\row }\pard \ltrpar\ql \li0\ri0\sl100\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13728027 
\par }}{\headerf \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 
\ltrch\fcs0 \cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1  }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13728027 
\par }}{\footerf \ltrpar \ltrrow\trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 \hich\f1 COPYRIGHT \'a9\loch\f1  2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved
\par }\pard \ltrpar\ql \li0\ri0\sl200\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK "https://marketintelligence.spglobal.com/" }}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 spglobal.com/mark\hich\af1\dbch\af1\loch\f1 etintelligence}}}\sectd \ltrsect
\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs14\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \cell }\pard \ltrpar\qr \li0\ri0\sl340\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
{\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 PAGE}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\hich\af1\dbch\af1\loch\f1 1}}}\sectd \ltrsect\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs20\cf22\loch\af1\hich\af1\dbch\af1\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph108\trrh200\trleft0\trbrdrt\brdrs\brdrw10 
\trbrdrl\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx8000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10600\row }\pard \ltrpar\ql \li0\ri0\sl100\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid13728027 
\par }}{\*\pnseclvl1\pnucrm\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl2\pnucltr\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl3\pndec\pnstart1\pnindent720\pnhang {\pntxta .}}{\*\pnseclvl4\pnlcltr\pnstart1\pnindent720\pnhang {\pntxta )}}
{\*\pnseclvl5\pndec\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl6\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl7\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl8
\pnlcltr\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}{\*\pnseclvl9\pnlcrm\pnstart1\pnindent720\pnhang {\pntxtb (}{\pntxta )}}\ltrrow\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph108\trrh800\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl\brdrs\brdrw10 
\trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx3500\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \lang1024\langfe1024\noproof\insrsid2058615 {\*\shppict{\pict{\*\picprop\shplid1026{\sp{\sn shapeType}{\sv 75}}{\sp{\sn fFlipH}{\sv 0}}
{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}\picscalex100\picscaley99\piccropl0\piccropr0\piccropt0\piccropb0\picw4198\pich1305\picwgoal2380\pichgoal740\pngblip\bliptag255{\*\blipuid 4de05a9ccfd0b11549afdb0eb59be2f2}
89504e470d0a1a0a0000000d49484452000000fb000000540802000000cb5ad6ca0000000467414d410000b18f0bfc6105000000017352474200aece1ce90000
10104944415478daed9dcd8bd3ea17c7f307641f5c4a96429662562364251702032ec20537013776212e72172e2a7795d9c5dd6465364a41a4204205a1205810
0b2245a1d231334ec797fad20183b48b2c7e3f3ac7793c3e6f4d673ae3cb3d872eee6dd3e479f93ce739e77b9e8e46bfdfcfc87e3d6bb7dbff233b0233b22c33
c87e3d0b8280e824e2897832229e88275b88781a0232229e8c8c88272323e2c9c888783232229e8cecd7247ef8f4d9e0fa7a7ef1cae713cef6ca6a7ef1ca60fd
c6eee883e6fb3bcf5fe417af6cfff5f7ec2b7ffd3d58bff169e7cddcebc5d760fdc6e0d6edd78f9f4ca7d3853a903f680fd692fcc22568c0ec56b76e7f2d0ac9
957bfdfa7cc2c92f5e39d8607d19efc21d3e9f70debd1c2c7726066bc9219b47b600f15f8be2d5e5ab6c3ab9d7e0fabac850599683eca678f1c793a735d06f3e
7ca47a0abcde9f3a3bb875bb2ccbb94ddf1d7d00d0a537d97cf88888279313ffb5283e9e3cad0731bf7089a370f8f419a6fced9973ec7fb75756a55eb60af1df
d6d85aa26ff7f0e9b3b96d1e643789783209f11bfffcfb9dec8b57debd1cc06be3de7dcc310710fbd6abcb572114f9b4f3e6fda9b3f0e6f0e9b3b9c44324c35e
b8199f4f383bcf5f68bc3bc63dbf70297fd07ef772b0f3fcc5e0da1abe09e69288279b11bf3bfac06671e39f7fc5d00562740815f047ec5b38d067d3b671e7ee
5ce2bf8c77b94fdfbd1c3094f30b97548dc66b63b07e438cecd9a7af2e5f25e2c97e207ee7f90b368bd2f87be3de7de9050ccdd1e696386d22885588c777e016
18331c836d9d0fa5d76c9d0fc59be8899f4ea7b3c4fdd66d48a3371f3e129bc7113fdadc82eb675fc96e6ab297d9e693dd842b5f5dbeba71e7ae18f511f1c744
3cf6880bf92d163f30678c3db42a26994b3c6e8f341978fdf809bb404c4f199a2c3663e98786f8d1e616dbca34e92f265e9ae80f6edd161792f4caf7a7cebe7e
fc8488ffc951cdf6ca2a76d873b778c6f7602dd9b873b74a4032dfc7efeb3f1f4f9e96af34241049efa0d43115c4e32524d5a9a4c4ab5edc52d728609ca845c4
1f5fe6ca6200e67e60ffddf8e7df8d7bf717951ab7ce872aa1662ef15f8b82e5caaa888591f1f9845345c4d4135f96257be2c793a707eb376629fb9dbb386567
23c011bf753e7cfdf809a4f86cb5bf3d738e751fcb591bf7eec3fb5fc6bb4c54c58913117f7cc47f19ef328d45254d4aeb50af1f3fe124c2c1b535a09083637b
6555241e7061afcd878fb65756351182483c1765496b5b8c3f29f1384bc1fa12ce161897b853db2babb85836dadcfa0ef77ed69e3f6833df211576f13e46c41f
1ff1a0f771e2a0b80573018fb4fcc402df2ac46b5e5be74395ff56118f570b7eb19d444abcd4dd7e7bd0fa0d2efdc59ddab8779fdf43f66f35b8b6a61ff4772f
07621788f863259ecde8e6c3474c7fe01cfff6ca2aa310839b5fb884a355f0949f76deb05d7e2665ec435085f8fce215cdd186e512cffa286e2938260177ae57
2707b76e4be3b1596df8419b6d41dcae48c4ff4ce2a5de0847f9202f4ca7d3efa0eca15c9625f3701f4f9ede79fe8291cdc9942ae2217918ac2573f5a2c1f575
a99833dadc62019234bb1589ff5a149a200a7b62d8dff4c43395094ba26c19a85e44fc7113cf405165a83f60b157766528bc3f7596c5b2d3e99479d9f7a7ce32
afcfedfe73b59ab986236f95b284afd1105f966545e261cfd113bf71e72edbd6b8b8883d175ed88910f1c7aec7ef73a0d2467079151c36a39645e72c28123360
6e211d9e78162f69ea5c3827d147354c86e7ce50704d15d371b114c0361fb83f56815e5dbe8ab7231c2f11f1c74d3cf6435297895d5dfea08ddff978f2342744
7eda7983e3545ce45f16f11853e9394dbc24e4c4a37201aba3bd3d738ecb95d9b2610b1b13cfa5a7986f90f0f1b8718dc4632e215e5dcd205b02f1988fb767ce
7127c0361f3ec272356cee65597e2f365dbc8245baaf4581b7ecadf32177de7d29c4e3ba2c57bcdc79fe024be9f8290c6e1c8cfdb063a062136e270bcc38010a
3f17671730869878bc21e0ca344e4570eea12968902d2173e574c66f1528e1e839def77142f6f6ccb9c1f5f5d9f9c76b6b6254c3e98c4b219e8b5b60358a3208
f7141cdce3e001df0a7e5382172df6fd62cd35bf7069b07e03cb442c38e46b5b7b43244ac05be743d801b8d22fc53647487c59969a6238f37f18dc9938b31f24
485f786a5f5dbe2a95350f43fc743ac53225f77a7be61ccb23d953be8c77b1fb67484da753555fb6575671408289e70ad5cc59e04ee1537a1ce5f8899004e3d4
9f883f0e75327fd0164f53c1d04b659cd96fa07ed42298db837c007f2ad5e30f433c438a6bf3cc9b5e5bfb32de65e10a7eca68738bed5d1c5283eca6583fe642
32463c942638873d584bc41e0d9f3ee3f63df839c168738b2d3f36bc9ae6911da11eff69e70de895558864876c675bf6bdfb8787f860061aebe1c3dfddd10738
065cf1faaf450163a5ff792e93807fd6f890e988272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c8827233b0cf1f0af8756ffa300799e
6759d6ed768fb459bd5e2f0882e217384238994cb22c1b0e87bfce9c351a8d2491fc5dce24491a8d86f87e9665cd669358ff463c58f51109c3d0308c7abd7ea4
cd6ab7db86618cc7e39f3e40e3f1d8308c5feadf13aed7ebd27f09300802e9bc1886e1380eb1fe03f19ee755b97a341ac1f5bf35f1cd66b3bacf5e22f1ed76bb
dfef1f3ff14110445144ac7f27def77dc330aa4c469224ce9efdd6c42f44f01289771c27cbb2e3279e8c273ecb32d775e7ba81b22c6ddb6e341a443c11ffdb13
df6c364dd3d4678a9d4e07ae21e2ff6ce247a3519665ad56eb4f267e329998a629cdf499f9be0ffb8086f8a2289acd6618864110d46ab546a331994c54c1f468
340231a4dbed8264c410d7100fe249afd713df6f369bb55a2d0882388ec50bdaed363cc5308c5aad96ed9b9e6615f1cd6633cf73786eabd582e7866128aa58ec
b996650541a0792eee42bd5eef743a4b21bebd67d25be5799ea669b0675114f5fbfd5eaf671886b423fd7e3f4912b838cb32957f64f308dd6130e8c3e63ccfe3
38869bc7710c6ca8628d56ab154511b479d195f98d7818474d463f1c0e59acaf22bed3e9589665db76bd5ecfb22c8a226bcfa45d751ca7dd6ee779eebaaeb16f
ec4a15f16559fabeef791eb7907abd1e3cba56aba5690a99491004f832365b8661b8ae1bec9b54e99b4b3c38ec5eaf67db36a01c0481e338800b567bd9734dd3
741c47f55ce88265596118665906edf43c4f1c840364aed2eb61f13b8e1345511cc79ee7a984bbb22c6bb51ab4278e6340c5344da9c467184677cfa03b786454
5b5c9aa68661d8b6cd2e56f9dfe17068dbb6699ab0eac2308451ad2e457c271e985609ed4992b8aecb265b1cd93ccf0dc348d394735abeef3b8ee48f003b8ed3
68346cdb0ec3505cd052e2cbb20cc3d0711ceefd7ebf6f9a66bd5ec74fc9f3dcb66ddff7c5472f25aa8141b02c2b4d53bcae1a8d866118d255a4896aa00b6118
e25b8d4623d7751dc7e196f75288ef743a8661705441e02a363e0c43cbb2b83d07168c38328081699a5c9d07ae1701eb76bbf015d6cdb22c1b8d86699a711c73
e1966559beef63008aa2f07ddfb2ac8a31b081579ee779b55a4dba8f5896c516b494f85aad1686a16a7310fb09eb58151d4989874d435c1e9ee749d36e78b4e8
8796453c4447e257a228b26d5bbac855c40741e0fbbe344a14115c0af12aad22cb32d334f11a0322c52811fc20773113bca56b5eec26c821d29624496218069e
6ed85bc481859b48e7620ef1aa58a2d56ae18e49896f369baa40cdb22c718702e25551bed8927abd6e9aa6b87975bb5d4dce0d72ead1112ff52be03ec595a922
1e56a66a5f06aaf0341f9ef8b22c5583008d811485f932154cb020399f6218866a66c1738b6849a78fbb39fcaf2a0669369b15a58e1f88075fce4526e044f150
2eaad54867da711ca95793120f8e47ea66eaf5baa67c06fe891b8865112fddd3204491d63754c44352ab6a00a492f86e87277e3299a822582832b28f606d684a
f2beef73eb41b5f5b169c5efc471ac1a46e977552e129a5d655a0d2e9f489284db91450fa4217e3c1e336982a56810d249e3e02ac4c3f2354d539abf8314d057
18b85b0ebe25c6f14b213e8e63d775f55dc00d584a5463dbb6b431f038e623a0fb8d4643d5bc300c398f23a6731ae27ddfe7827595359b4d504154a6c98c75c4
c35ac1398ae84455992ba82e2047a469ca6438cbb2a4c4abc605130fff11c731a4a1e29558ea51d91111af494317221e8e2ae96de9c4c3b6c93991c964e2380e
f6d02048e88d8b1b357b82483cd434ab4c0424be7a3b08f1cc6bb221304d93933c45e2c7e331e850d2605445bca67d3034ad568b9de101df230e2568bdc75f81
5a22f1fac0ecf07abc9478c8f6400fe9743add6e374912cbb25cd7c5513578401cd61f667845e23dcfd3abc33807d0c47e07d1e3b9d817d885ad84cb8e45e221
ff901e3986213b18f1a06de314ca344d2e28c7b2e96f4a3c14bc8f9978d836d334659ba4e779699a8a93a8d2dd97427c1445151d16e433873f402e211e563fac
3ce912148987228ba69307239e53d38ba280028d1877aa06a2d7eb49d5c9ea85bae5122f0de4207250f9d15eafc73de8f0c48fc7e3b9874a2aeea28d46836bf9
42c4434d46ea2ba1fc82b51a4dbd087eb651e5671ef2e887692352d54c243e4d53e98e33994c6cdb3e30f1aaca141ed0b22c353ba3ebba2204aeeb56dc49974b
7c18862a74541f81f7e1788de3589ad254271eb6f18a3f03c27b7e959e2e443c688eaaad8fab034061587a67cff32afe06404e3cb403ea5b52b5911b59587f9c
e39c4c265114b97b26ce4415e2a5f26a1004966561ff04923c37ca655982842f2e9b5aade6baae4ae73a3ae2410793760a04312e872bcb328e63f156100589bc
d6eb7569802755272dcbf23c2f43061515d5987b9ec78d2454b5c5dd6621e25977b88d02ce5c70fb39abc7717d57557f17201eb0e0441bbd56c34e68f57abd7e
bf0f09806559c3e1107600ce871d9878d891b92a1df8033891d2e974e0fcb365592ac9991dccc8b24c5f5b5822f14551d8b6cd38e306042afcbeefc38f2aa10b
a26cc07402289ae2a7803386a32fd8254be378688c54f108828083bb280a7034711cb7dbed66b3094bd1f77d31345a9478885ea0000f231345112816a257eaf7
fbd077364a7086aafaa1d459f7a4ed2b8aa2dfef4b37be288aa48a529ee77000038e6ab55a2d188eb22ce1801e7713cda2d4ffceb5dd6e8bba509ee750de67a7
a334716aafd7abd56a5005d3ebc130d962f14bd3fee170a892ada091aeeb4a0f748c462328a4c3b1aa5aada63a4208f711e7aedbedc2d14bdce064cfc4f68b64
c33956dff7a5e5ed56ab05e7db807595aa281d2e3cadd28f5aad16cba135778019810a866118b00f2c2625fd8fecbf67dd6ed7b66d8d4780137e7f64df89f8ff
a2d5f74c7381f43c12114ff61b13af8fe5d2345da82846c493fdea518dea9c12e421d20385443cd96f6c711c83d2d7ed76f1792cd0498220a8fe47bb8878b2df
c33a9d0ec8824c9704e9e34ffd4d37114ff65f34229e8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c88272323e2c9c8887832b23fc1fe0ffddae68623b2774b0000000049454e44ae426082}}{\nonshppict
{\pict\picscalex47\picscaley44\piccropl0\piccropr0\piccropt0\piccropb0\picw8855\pich2963\picwgoal5020\pichgoal1680\wmetafile8\bliptag255\blipupi72{\*\blipuid 4de05a9ccfd0b11549afdb0eb59be2f2}
89504e470d0a1a0a0000000d49484452000000fb000000540802000000cb5ad6ca0000000467414d410000b18f0bfc6105000000017352474200aece1ce90000
10104944415478daed9dcd8bd3ea17c7f307641f5c4a96429662562364251702032ec20537013776212e72172e2a7795d9c5dd6465364a41a4204205a1205810
0b2245a1d231334ec797fad20183b48b2c7e3f3ac7793c3e6f4d673ae3cb3d872eee6dd3e479f93ce739e77b9e8e46bfdfcfc87e3d6bb7dbff233b0233b22c33
c87e3d0b8280e824e2897832229e88275b88781a0232229e8c8c88272323e2c9c888783232229e8cecd7247ef8f4d9e0fa7a7ef1cae713cef6ca6a7ef1ca60fd
c6eee883e6fb3bcf5fe417af6cfff5f7ec2b7ffd3d58bff169e7cddcebc5d760fdc6e0d6edd78f9f4ca7d3853a903f680fd692fcc22568c0ec56b76e7f2d0ac9
957bfdfa7cc2c92f5e39d8607d19efc21d3e9f70debd1c2c7726066bc9219b47b600f15f8be2d5e5ab6c3ab9d7e0fabac850599683eca678f1c793a735d06f3e
7ca47a0abcde9f3a3bb875bb2ccbb94ddf1d7d00d0a537d97cf88888279313ffb5283e9e3cad0731bf7089a370f8f419a6fced9973ec7fb75756a55eb60af1df
d6d85aa26ff7f0e9b3b96d1e643789783209f11bfffcfb9dec8b57debd1cc06be3de7dcc310710fbd6abcb572114f9b4f3e6fda9b3f0e6f0e9b3b9c44324c35e
b8199f4f383bcf5f68bc3bc63dbf70297fd07ef772b0f3fcc5e0da1abe09e69288279b11bf3bfac06671e39f7fc5d00562740815f047ec5b38d067d3b671e7ee
5ce2bf8c77b94fdfbd1c3094f30b97548dc66b63b07e438cecd9a7af2e5f25e2c97e207ee7f90b368bd2f87be3de7de9050ccdd1e696386d22885588c777e016
18331c836d9d0fa5d76c9d0fc59be8899f4ea7b3c4fdd66d48a3371f3e129bc7113fdadc82eb675fc96e6ab297d9e693dd842b5f5dbeba71e7ae18f511f1c744
3cf6880bf92d163f30678c3db42a26994b3c6e8f341978fdf809bb404c4f199a2c3663e98786f8d1e616dbca34e92f265e9ae80f6edd161792f4caf7a7cebe7e
fc8488ffc951cdf6ca2a76d873b778c6f7602dd9b873b74a4032dfc7efeb3f1f4f9e96af34241049efa0d43115c4e32524d5a9a4c4ab5edc52d728609ca845c4
1f5fe6ca6200e67e60ffddf8e7df8d7bf717951ab7ce872aa1662ef15f8b82e5caaa888591f1f9845345c4d4135f96257be2c793a707eb376629fb9dbb386567
23c011bf753e7cfdf809a4f86cb5bf3d738e751fcb591bf7eec3fb5fc6bb4c54c58913117f7cc47f19ef328d45254d4aeb50af1f3fe124c2c1b535a09083637b
6555241e7061afcd878fb65756351182483c1765496b5b8c3f29f1384bc1fa12ce161897b853db2babb85836dadcfa0ef77ed69e3f6833df211576f13e46c41f
1ff1a0f771e2a0b80573018fb4fcc402df2ac46b5e5be74395ff56118f570b7eb19d444abcd4dd7e7bd0fa0d2efdc59ddab8779fdf43f66f35b8b6a61ff4772f
07621788f863259ecde8e6c3474c7fe01cfff6ca2aa310839b5fb884a355f0949f76deb05d7e2665ec435085f8fce215cdd186e512cffa286e2938260177ae57
2707b76e4be3b1596df8419b6d41dcae48c4ff4ce2a5de0847f9202f4ca7d3efa0eca15c9625f3701f4f9ede79fe8291cdc9942ae2217918ac2573f5a2c1f575
a99833dadc62019234bb1589ff5a149a200a7b62d8dff4c43395094ba26c19a85e44fc7113cf405165a83f60b157766528bc3f7596c5b2d3e99479d9f7a7ce32
afcfedfe73b59ab986236f95b284afd1105f966545e261cfd113bf71e72edbd6b8b8883d175ed88910f1c7aec7ef73a0d2467079151c36a39645e72c28123360
6e211d9e78162f69ea5c3827d147354c86e7ce50704d15d371b114c0361fb83f56815e5dbe8ab7231c2f11f1c74d3cf6435297895d5dfea08ddff978f2342744
7eda7983e3545ce45f16f11853e9394dbc24e4c4a37201aba3bd3d738ecb95d9b2610b1b13cfa5a7986f90f0f1b8718dc4632e215e5dcd205b02f1988fb767ce
7127c0361f3ec272356cee65597e2f365dbc8245baaf4581b7ecadf32177de7d29c4e3ba2c57bcdc79fe024be9f8290c6e1c8cfdb063a062136e270bcc38010a
3f17671730869878bc21e0ca344e4570eea12968902d2173e574c66f1528e1e839def77142f6f6ccb9c1f5f5d9f9c76b6b6254c3e98c4b219e8b5b60358a3208
f7141cdce3e001df0a7e5382172df6fd62cd35bf7069b07e03cb442c38e46b5b7b43244ac05be743d801b8d22fc53647487c59969a6238f37f18dc9938b31f24
485f786a5f5dbe2a95350f43fc743ac53225f77a7be61ccb23d953be8c77b1fb67484da753555fb6575671408289e70ad5cc59e04ee1537a1ce5f8899004e3d4
9f883f0e75327fd0164f53c1d04b659cd96fa07ed42298db837c007f2ad5e30f433c438a6bf3cc9b5e5bfb32de65e10a7eca68738bed5d1c5283eca6583fe642
32463c942638873d584bc41e0d9f3ee3f63df839c168738b2d3f36bc9ae6911da11eff69e70de895558864876c675bf6bdfb8787f860061aebe1c3dfddd10738
065cf1faaf450163a5ff792e93807fd6f890e988272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c8827233b0cf1f0af8756ffa300799e
6759d6ed768fb459bd5e2f0882e217384238994cb22c1b0e87bfce9c351a8d2491fc5dce24491a8d86f87e9665cd669358ff463c58f51109c3d0308c7abd7ea4
cd6ab7db86618cc7e39f3e40e3f1d8308c5feadf13aed7ebd27f09300802e9bc1886e1380eb1fe03f19ee755b97a341ac1f5bf35f1cd66b3bacf5e22f1ed76bb
dfef1f3ff14110445144ac7f27def77dc330aa4c469224ce9efdd6c42f44f01289771c27cbb2e3279e8c273ecb32d775e7ba81b22c6ddb6e341a443c11ffdb13
df6c364dd3d4678a9d4e07ae21e2ff6ce247a3519665ad56eb4f267e329998a629cdf499f9be0ffb8086f8a2289acd6618864110d46ab546a331994c54c1f468
340231a4dbed8264c410d7100fe249afd713df6f369bb55a2d0882388ec50bdaed363cc5308c5aad96ed9b9e6615f1cd6633cf73786eabd582e7866128aa58ec
b996650541a0792eee42bd5eef743a4b21bebd67d25be5799ea669b0675114f5fbfd5eaf671886b423fd7e3f4912b838cb32957f64f308dd6130e8c3e63ccfe3
38869bc7710c6ca8628d56ab154511b479d195f98d7818474d463f1c0e59acaf22bed3e9589665db76bd5ecfb22c8a226bcfa45d751ca7dd6ee779eebaaeb16f
ec4a15f16559fabeef791eb7907abd1e3cba56aba5690a99491004f832365b8661b8ae1bec9b54e99b4b3c38ec5eaf67db36a01c0481e338800b567bd9734dd3
741c47f55ce88265596118665906edf43c4f1c840364aed2eb61f13b8e1345511cc79ee7a984bbb22c6bb51ab4278e6340c5344da9c467184677cfa03b786454
5b5c9aa68661d8b6cd2e56f9dfe17068dbb6699ab0eac2308451ad2e457c271e985609ed4992b8aecb265b1cd93ccf0dc348d394735abeef3b8ee48f003b8ed3
68346cdb0ec3505cd052e2cbb20cc3d0711ceefd7ebf6f9a66bd5ec74fc9f3dcb66ddff7c5472f25aa8141b02c2b4d53bcae1a8d866118d255a4896aa00b6118
e25b8d4623d7751dc7e196f75288ef743a8661705441e02a363e0c43cbb2b83d07168c38328081699a5c9d07ae1701eb76bbf015d6cdb22c1b8d86699a711c73
e1966559beef63008aa2f07ddfb2ac8a31b081579ee779b55a4dba8f5896c516b494f85aad1686a16a7310fb09eb58151d4989874d435c1e9ee749d36e78b4e8
8796453c4447e257a228b26d5bbac855c40741e0fbbe344a14115c0af12aad22cb32d334f11a0322c52811fc20773113bca56b5eec26c821d29624496218069e
6ed85bc481859b48e7620ef1aa58a2d56ae18e49896f369baa40cdb22c718702e25551bed8927abd6e9aa6b87975bb5d4dce0d72ead1112ff52be03ec595a922
1e56a66a5f06aaf0341f9ef8b22c5583008d811485f932154cb020399f6218866a66c1738b6849a78fbb39fcaf2a0669369b15a58e1f88075fce4526e044f150
2eaad54867da711ca95793120f8e47ea66eaf5baa67c06fe891b8865112fddd3204491d63754c44352ab6a00a492f86e87277e3299a822582832b28f606d684a
f2beef73eb41b5f5b169c5efc471ac1a46e977552e129a5d655a0d2e9f489284db91450fa4217e3c1e336982a56810d249e3e02ac4c3f2354d539abf8314d057
18b85b0ebe25c6f14b213e8e63d775f55dc00d584a5463dbb6b431f038e623a0fb8d4643d5bc300c398f23a6731ae27ddfe7827595359b4d504154a6c98c75c4
c35ac1398ae84455992ba82e2047a469ca6438cbb2a4c4abc605130fff11c731a4a1e29558ea51d91111af494317221e8e2ae96de9c4c3b6c93991c964e2380e
f6d02048e88d8b1b357b82483cd434ab4c0424be7a3b08f1cc6bb221304d93933c45e2c7e331e850d2605445bca67d3034ad568b9de101df230e2568bdc75f81
5a22f1fac0ecf07abc9478c8f6400fe9743add6e374912cbb25cd7c5513578401cd61f667845e23dcfd3abc33807d0c47e07d1e3b9d817d885ad84cb8e45e221
ff901e3986213b18f1a06de314ca344d2e28c7b2e96f4a3c14bc8f9978d836d334659ba4e779699a8a93a8d2dd97427c1445151d16e433873f402e211e563fac
3ce912148987228ba69307239e53d38ba280028d1877aa06a2d7eb49d5c9ea85bae5122f0de4207250f9d15eafc73de8f0c48fc7e3b9874a2aeea28d46836bf9
42c4434d46ea2ba1fc82b51a4dbd087eb651e5671ef2e887692352d54c243e4d53e98e33994c6cdb3e30f1aaca141ed0b22c353ba3ebba2204aeeb56dc49974b
7c18862a74541f81f7e1788de3589ad254271eb6f18a3f03c27b7e959e2e443c688eaaad8fab034061587a67cff32afe06404e3cb403ea5b52b5911b59587f9c
e39c4c265114b97b26ce4415e2a5f26a1004966561ff04923c37ca655982842f2e9b5aade6baae4ae73a3ae2410793760a04312e872bcb328e63f156100589bc
d6eb7569802755272dcbf23c2f43061515d5987b9ec78d2454b5c5dd6621e25977b88d02ce5c70fb39abc7717d57557f17201eb0e0441bbd56c34e68f57abd7e
bf0f09806559c3e1107600ce871d9878d891b92a1df8033891d2e974e0fcb365592ac9991dccc8b24c5f5b5822f14551d8b6cd38e306042afcbeefc38f2aa10b
a26cc07402289ae2a7803386a32fd8254be378688c54f108828083bb280a7034711cb7dbed66b3094bd1f77d31345a9478885ea0000f231345112816a257eaf7
fbd077364a7086aafaa1d459f7a4ed2b8aa2dfef4b37be288aa48a529ee77000038e6ab55a2d188eb22ce1801e7713cda2d4ffceb5dd6e8bba509ee750de67a7
a334716aafd7abd56a5005d3ebc130d962f14bd3fee170a892ada091aeeb4a0f748c462328a4c3b1aa5aada63a4208f711e7aedbedc2d14bdce064cfc4f68b64
c33956dff7a5e5ed56ab05e7db807595aa281d2e3cadd28f5aad16cba135778019810a866118b00f2c2625fd8fecbf67dd6ed7b66d8d4780137e7f64df89f8ff
a2d5f74c7381f43c12114ff61b13af8fe5d2345da82846c493fdea518dea9c12e421d20385443cd96f6c711c83d2d7ed76f1792cd0498220a8fe47bb8878b2df
c33a9d0ec8824c9704e9e34ffd4d37114ff65f34229e8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c8c88272323e2c9c888783232229e8c88272323e2c9c8887832b23fc1fe0ffddae68623b2774b0000000049454e44ae426082}}}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 \trowd \irow0\irowband0\lastrow \ltrrow\ts11\trgaph108\trrh800\trleft0\trbrdrt\brdrs\brdrw10 \trbrdrl
\brdrs\brdrw10 \trbrdrb\brdrs\brdrw10 \trbrdrr\brdrs\brdrw10 \trbrdrh\brdrs\brdrw10 \trbrdrv\brdrs\brdrw10 
\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx3500\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\par }\pard \ltrpar\ql \li0\ri0\sl300\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs46\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 
Bristol-Myers Squibb Company NYSE:BMY}{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid10976062 
\par }\pard \ltrpar\ql \li0\ri0\sl280\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs60\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Special Call}{\rtlch\fcs1 
\af1 \ltrch\fcs0 \b\fs60\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Monday, April 16, 2018 11:00 PM GMT\page }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par \ltrrow}\trowd \irow0\irowband0\ltrrow\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trftsWidthA1\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband
\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7500\pard \ltrpar\ql \li0\ri0\sl260\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Table of Contents}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf20\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1  }{\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs50\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 
\trowd \irow0\irowband0\ltrrow\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trftsWidthA1\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband
\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7000\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx7500\row \ltrrow}\trowd \irow1\irowband1\ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 
 HYPERLINK \\l "0" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000030000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Call Participants}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 
\b\fs18\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 ........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 3}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \trowd \irow1\irowband1\ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row \ltrrow}\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\hich\af1\dbch\af1\loch\f1  HYPERLINK \\l "1" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000031000000}}}{\fldrslt {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Presentation}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 ........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 4}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \trowd \irow2\irowband2\ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row \ltrrow}\pard \ltrpar\ql \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\hich\af1\dbch\af1\loch\f1  HYPERLINK\hich\af1\dbch\af1\loch\f1  \\l "2" }{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 {\*\datafield 08d0c9ea79f9bace118c8200aa004ba90b02000000080000000200000032000000}}}{\fldrslt {
\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 Question and Answer}}}\sectd \ltrsect\linex0\headery400\footery400\colsx708\endnhere\titlepg\sectlinegrid360\sectdefaultcl\sftnbj {\rtlch\fcs1 
\af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qc \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 ........................................................................................................................................................}{\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar\qr \li0\ri0\sl400\slmult1\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 
\fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 8}{\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \cell }\pard \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \fs20\cf1\loch\af1\hich\af1\dbch\af1\insrsid10976062 \trowd \irow3\irowband3\lastrow \ltrrow
\ts11\trgaph108\trleft0\trftsWidth2\trwWidth5000\trftsWidthB3\trautofit1\trpaddl108\trpaddt20\trpaddb100\trpaddr108\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalc\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx4200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 \cellx10200\clvertalc\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth1\clpadt0\clpadr0\clpadft3\clpadfr3\clcbpatraw8 
\cellx10900\row }\pard \ltrpar\ql \li0\ri0\sl280\slmult1\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs36\cf20\loch\af1\hich\af1\dbch\af1\insrsid10976062 \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\headerr \ltrpar \pard\plain \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 \hich\af1\dbch\af1\loch\f1 BRISTOL-MYERS SQUIBB COMPANY  SPECIAL CALL   |    APR 16, 2018}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid13728027 
\par }{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }{\rtlch\fcs1 \af0 \ltrch\fcs0 \insrsid2058615 {\shp{\*\shpinst\shpleft0\shptop0\shpright10656\shpbottom0\shpfhdr0\shpbxcolumn\shpbxignore\shpbypara\shpbyignore\shpwr3\shpwrk0\shpfblwtxt0\shpz0\shplid2051
{\sp{\sn shapeType}{\sv 20}}{\sp{\sn fFlipH}{\sv 0}}{\sp{\sn fFlipV}{\sv 0}}{\sp{\sn fFillOK}{\sv 0}}{\sp{\sn fNoFillHitTest}{\sv 0}}{\sp{\sn lineWidth}{\sv 12700}}
{\sp{\sn dhgt}{\sv 251657216}}{\sp{\sn fEditedWrap}{\sv 0}}{\sp{\sn fBehindDocument}{\sv 0}}{\sp{\sn fIsButton}{\sv 0}}{\sp{\sn fPseudoInline}{\sv 0}}{\sp{\sn fLayoutInCell}{\sv 1}}}{\shprslt{\*\do\dobxcolumn\dobypara\dodhgt8192
\dpline\dpptx0\dppty0\dpptx10656\dppty0\dpx0\dpy0\dpxsize10656\dpysize0\dplinew20\dplinecor0\dplinecog0\dplinecob0}}}}{\rtlch\fcs1 \af1 \ltrch\fcs0 \b\fs18\cf1\loch\af1\hich\af1\dbch\af1\insrsid13728027 
\par }}{\footerr \ltrpar \ltrrow\trowd \ltrrow\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid13728027 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 3}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow
}\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt
\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid13728027 
\par }}\ltrrow\trowd \irow0\irowband0\ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid13728027 {\*\bkmkstart 0}{\*\bkmkend 0}\cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
\rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid13728027 \trowd \irow0\irowband0\ltrrow
\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \irow1\irowband1\ltrrow
\ts11\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 
{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid13728027 Call Participants}{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f40\fs48\cf1\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
\rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f40\fs48\cf1\insrsid13728027 \trowd \irow1\irowband1\ltrrow
\ts11\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone 
\clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \irow2\irowband2\lastrow \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx3547\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx7094\clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx10641\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 
\ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 EXECUTIVES}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Fouad  Namouni}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Head of Oncology Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line 
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  
\line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Sabine Maier}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Saurabh  Saha}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior VP & Global Head of Translational Medicine}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Unknown Executive}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 ANALYSTS}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Andrew Simon Baum}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Citigroup Inc, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Ardalan  Arfaei}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 BMO Capital Markets Equity Research}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Christopher Thomas Schott}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 JP Morgan Chase & Co, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 David Reed Risinger}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Morgan Stanley, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line \cell  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Geoffrey Christopher Meacham}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Gregory B. Gilbert}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Deutsche Bank AG, Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Jamilu E. Rubin}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Goldman Sachs Group Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Jason Matthew Gerberry}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 BofA Merrill Lynch, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Matthew Christopher Phipps}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 William Blair & Company L.L.C., Research Division}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Richard Wagner}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Stephen Michael Scala}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Cowen and Company, LLC, Research Division}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Vamil Kishore Divan}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Cr\'e9dit Suisse AG, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027  \line \cell \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 
\rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf1\insrsid13728027 \trowd \irow2\irowband2\lastrow \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx3547\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx7094\clvertalt\clbrdrt
\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth3547\clcbpatraw8 \cellx10641\row }\pard \ltrpar\ql \li0\ri0\widctlpar\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0\itap0 {\rtlch\fcs1 \af0 
\ltrch\fcs0 \insrsid13728027 \sect }\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr \ltrpar \ltrrow\trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid13728027 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 7}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow
}\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt
\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f40\fs16\insrsid13728027 
\par }}\ltrrow\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb
\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027 {\*\bkmkstart 1}{\*\bkmkend 1}\cell }\pard\plain \ltrpar
\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027 
\trowd \irow0\irowband0\lastrow \ltrrow\ts11\trrh-1\trleft0\trftsWidth3\trwWidth10640\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind0\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid13728027 Presentation}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 [indisc
ernible] And stay for all of you, and we are pleased to have the opportunity to give your our perspective on the data and what it means for the company moving forward. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Before we get started, I'd just let you know the structure of the day, how it's goi
ng to work. Tom and Fouad are going to talk a little about the data and the implications and how we think about it. Hopefully, that will only go for about 20 minutes or so and then will be able to take your questions. Well aware that you have another meet
ing that you would be either like to get to or dial in to, so we'll be very respectful of your time. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
For questions, in addition to Tom and Fouad, Murdo, will join us on stage because I know there's a lot of questions about the commercial implications a
nd what -- why we might play in lung cancer as a result of the data sets today, so Murdo will join up on stage to just make it easier. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 In addition, some people who are also here to see you know, in case you have questions, Giovanni, I think everybody 
knows our CEO is here. Johanna Mercier runs our U.S. business, working for Murdo, she is here. We have Steve Averbuch and Saurabh Saha. Saurabh leads our translational organization which, obviously, has a lot of relevance to PMB, and Steve Averbuch leads 
our biomarker and diagnostic group, so first question, specifically about that. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
And we have Sabine Maier here, who leads oncology development for Fouad, for the -- leads lung oncology development, and Adam Lenkowsky, who runs our oncology business in t
he U.S. So if there's other folks who you want to talk to, either during the Q&A or afterwards for a few minutes, we'll be here. This is our legal disclaimer, and I will turn it over to Tom. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
John, thank you very much. I want to welcome you all here tonight, I just want to start off by saying, how incredibly proud Bristol-Myers is today to be making this important advance in precision medicine. Personalized medicine, precision therapeuti
cs has been the Holy Grail of what we work for in cancer. And as Alice Shaw said when she started the session, Alice said, "We are delighted that there are practice-changing studies being presented today and being published in the New England Journal." It
 
really was a remarkable morning for lung cancer and non-small cell lung cancer. What I want to focus on are couple of areas. First is a regimen, Opdivo + Yervoy. We have great faith and confidence in Opdivo + Yervoy. This is the first combination to impro
v
e survival in melanoma, to improve outcome in renal cell, and today you saw that we were able to come forward with a nonchemotherapy, chemotherapy-sparing IO-IO combination that improved progression free survival and produced an exciting overall survival 
curve in TMB high patients with lung cancer. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Most importantly, the responses and the clinical benefit was deep with excellent duration of response. Again, the data is early, but again showed excellent responses that were deep of excellent duration. And
 we did this across the PD-L1 spectrum and across the histology spectrum in this disease. Second, we were able to describe an important new biomarker in lung cancer, TMB. So as you know, TMB, looks at tumor mutational burden, it's a surrogate for neoantig
e
ns that could be driving the immune system. You'll hear more about that from Fouad when he speaks. What we did at Bristol-Myers was we followed the science. We followed the science to bring us, to understand TMB, to understand is there a patient populatio
n
 that derives excellent benefit in this setting. And we saw this retrospectively in looking at 026 and then we apply this to the 227 trial, and we're able to define the population that benefited from combination therapy, very, very important in this setti
ng to be able to identify this. This is yet another step in the evolution of biomarkers in this disease, in lung cancer. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 So when you think about, I think one of the most important points of 227 today is it provides a very clear path forward in non-small cell lung cancer for the combination of Opdivo and Yervoy. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
You heard from Dr. Rizvi. How it's important that all patients should be tested for TMB. And why is that? It's because information will be able to guide therapy more effectively. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Patien
ts want to understand the biology of their cancer. Physicians want to understand which regimen is most likely to help my patients. And then another element, and I know this from my role, working at mass channel and public health care, is increasingly the 
payers will drive testing. Because the payers want to know, whether or not, IO-IO or any IO could be a benefit. For example, what if patients who are TMB-low and PD-L1-low don't benefit from IO? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 That's saving us substantial amount of resources for our 
health plan, particularly, when we move into new population health models, which will become the predominant method of ensuring patients in the country within the next 5 years. So I believe strongly that we will be getting more TMB testing for all of the 
r
easons that we just outlined, and we look forward to sharing with you some of the ways we think this is going to evolve. But before we go into more detail on lung cancer, I just want to stress 2 other -- 3 actually, 3 other points from today that are impo
rtant for Bristol-Myers Squibb. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
First, along, and this is also in lung cancer, we presented data this morning, the first data in China, that showed that in second-line lung cancer, a PD-1 drug could improve outcome compared to docetaxel, something we'r
e very proud of. Second, this morning, we received, from the FDA, approval for the Opdivo + Yervoy regimen in patients who have renal cell carcinoma with poor to intermediate risk and major advance for patients in this setting. And third, we announced abo
u
t 1 hour and 45 minutes ago, a relationship with J&J and Janssen  -- or actually, Janssen and J&J is the same thing. A relationship with J&J and Janssen to develop Factor XIa. As all of you know, Eliquis and cardiovascular disease are very important to Br
i
stol-Myers Squibb. And this is the compounds that activated Factor XIa inhibitor that looks really exciting and may provide additional benefits over the established drugs, Xarelto and Eliquis in the future, and seeing the company that makes Xarelto and th
e
 company that makes Eliquis, coming together in this setting is, again, something we're very proud of as we move forward. So I just want to, again, just focus on a few things that came out of this. As we have been telling you for the past 6 to 7 weeks, si
n
ce the 227 data came out. This is an important result in lung cancer that's highly statistically significant. And you saw today, how it's clinically meaningful, how profound that PFS benefit is, and you saw the early OS curves. You also saw this benefit w
as independent of PD-L1 and histology. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
The data clearly supports TMB as an important new biomarker. I told you last year, when I began my role as CSO that Bristol-Myers will continue to be focused on understanding cancer biology and applying the princi
ples of translational medicine to improve outcome. This is an excellent example of that. This is also the third tumor with benefit demonstrated for Opdivo + Yervoy in a randomized trial. And again, we're very high on the contribution that Yervoy makes in 
n
on-small cell lung cancer. So much so, that we have 6 additional tumors that we're looking at in the combination with Opdivo + Yervoy in Phase III trials. And we have multiple drugs in discovery that target CTLA-4, that we're equally excited about as we g
o forward. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So again, clinically, meaningful response -- results. PFS is 0.58, benefit is driven by deep and durable responses. One of the features of responses to IO-IO is that these responses, once they're achieved, persist. And again, we've got to se
e the data emerge, we've got to continue to follow the science to take us there. But the preliminary analysis of this data looks very interesting and something we're very much encouraged by at this point. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 And the Opdivo and low dose Yervoy safety prof
ile was also consistent with prior trials. So I believe strongly, it's not just what I believe, Naiyer Rizvi mentioned it earlier today as well, that this supports the potential importance of assessing TMB as we move forward. And we think that the data fr
om 227 today give us a very clear path forward in treating lung cancer. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
When I think about, 30 years ago, when I started as a lung cancer doctor. One of the Holy Grails was coming up with a non-chemotherapy regimen that could help lung cancer patients,
 and we did it with gefitinib and erlotinib, we did it with crizotinib and the ELK drugs.  And now I think we've done it again with Opdivo and Yervoy for patients who're high-TMB. And to tell you more about the deep and durable responses we're seeing, I'd
 like to introduce Fouad Namouni, Fouad is the head of oncology development at BMS, and Fouad will share his impressions of the 227 data. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Fouad  Namouni}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Head of Oncology Development}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Hi, everyone. As you just heard from Tom, our strategy has really 
been a deep understanding of the biology of lung cancer. And looking at our pipeline, strong mechanisms like Opdivo and Yervoy that can synergize together and make this match -- the subgroup that we determined based on the biology of cancer. In this case,
 the tumor mutational burden high segment of patients. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Clearly, we have seen today in the presentation this morning that this is an important and impactful result in terms of Opdivo and Yervoy, improving progression-free survival versus chemotherapy in TMB-high patients. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
The 1-year PFS was 43% compared to 13% with chemotherapy in these patients. We also noticed, given the type of activity that you would expect with a strong combination of immunotherapy would be plateauing of the PFS [indiscernible]
 over time. What is behind this duration and plateauing of PFS? The type of response that we have with combination of strong immunotherapy agents. Increased response rate compare to chemotherapy, but it's not only that the increased response rate compared
 
to chemotherapy, but it is durable over time. In fact the median duration of response in the Opdivo + Yervoy group has not been reached yet. With a 95% CI lower limit of 12.2 months. The 1-year duration of response was 68% for Opdivo and Yervoy, and only 
25% of the responders on chemotherapy were still responding at 1 year. It is about the increase of response. It is about the durability of response, but it is also about the depth of response as we can see here on this Slide 10. \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 So what we have -- have
 we seen so far? One, an improvement in progression-free survival, almost triple -- more than triple in actually the 1-year PFS with some plateauing of the PFS curve. Two, good response rates that are durable and deep, and we have seen this across most of
 the groups we studied. In particular, across histologies, in the non-squamous and the squamous, and also across PD-L1 expression where the activity is strong in both PD-L1 negative patients -- or tumors and PD-L1 positive tumors. \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 We also wanted to rea
lly understand the contribution of ipilimumab and Yervoy, when combined together or when nivo is given alone. And this was looked at in Part 1A, the only part of the study where we are able to have ipi and nivo and nivo monotherapy and chemotherapy as a r
eference arm. And you can see an incremental in PFS from 16% in chemotherapy at 1 year to 29% at 1 year with nivolumab, and then nivolumab and ipilimumab get us to 42% of 1-year PFS. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 These are early survival data, and they are very encouraging. The 1-y
ear overall survival data with Opdivo and Yervoy was 67%. And even if the median PFS with chemotherapy was higher than expected in the most recent historical data or series, 16.4 months, Opdivo and Yervoy in these patient high TMB was able to add 7 months
 to that go to 23 months median of overall survival. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
And then that was across histology's. So if you look at the non-squamous patients in terms of overall survival. One, we can see that the median overall survival in non-squamous patients was not reach
ed for nivo and ipi, or nivolumab and ipilimumab. The 1-year overall survival for Opdivo and Yervoy was 70% in this non-squamous TMB 10 population of patients, consistent with other combination we have seen using chemotherapy and other agents with immunot
herapy. We are encouraged, this data is early, we will wait and follow the data as it matures over time. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
In terms of safety, the new and adapted regimen -- optimized regimen of nivolumab and low-dose ipilimumab that we optimize in CheckMate -012, there
 is still data in this study consistent in terms of safety with the data we have seen from CheckMate -012. And if a focus on Slide 16, on the immune related adverse events, with immunotherapy combination, we can see that the grade 3 and 4 are basically si
ngle digits and within the range of nivolumab monotherapy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
As Tom said, these are really paradigm changing or shifting data as recognized by the most prestigious journal of medicine in terms of impact -- medical impact. We are achieving a very good act
ivity in -- consistently across end point, with chemo-sparing regimen that I think -- as you heard from Tom and others, that is really needed for our patients. Tom? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Well, thank you very much. So we just want to finish with a couple of slides before we begin to take questions. \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So in summary, significant innovation in advancing the science in lung cancer. That's what we're here to talk about today. TMB will help patients, payers  and
 physicians to make better decisions about their treatment. It's part of the future of how we're going to be treating cancer. We believe for some time -- we have talked to you for some time that the market of lung cancer will continue to segment. Why will
 
it segment? It will segment because this is a heterogeneous disease. We've been saying that for quite some time now. It's not just one disease. This is no different in the way breast cancer was years ago before they recognized all the different subtypes o
f breast cancer. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Finding a role, like we have today, for a chemo-sparing regimen of Opdivo + Yervoy, we think is very important. But this also reinforces the need for new biomarkers as we go forward. Now I think an equally exciting piece of data was al
so presented this morning, and this is the data from Drew Pardoll's Group. 21 patients with stage III lung cancer treated with 2 doses of nivolumab. Dramatic pathologic benefits we're seeing in these patients. Two doses of nivolumab. Now what this shows y
ou, again, we are still early in understanding how these drugs work. What this study shows us, it tells us -- gives us a window into the biology of how these drugs respond. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 So to finish, significant opportunities remain to address unmet medical needs. 
Remember Roy Herbst when he said, the 30% of patient -- only 35% of patients are still on therapy in the year without any evidence of progression. We still have a long way to go in lung cancer. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Bristol-Myers Squibb looks forward to sharing with you im
portant readouts in lung, renal, hepatoma, gastric, small cell, head and neck cancer. Well look, as you saw on Dr. Pardoll's study, to broaden the use of Opdivo in earlier lines of therapy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 As we mentioned earlier -- as I mentioned to you a year ago, 
the principles of investing in cancer biology, of investing in transitional medicine and following the science underlie the presentations that we've made to you here today. I think it's incredibly important that we begin to embrace the principles of preci
sion medicine and personalized medicine to be able to give the best options for our patients. \line Now I would like to ask Murdo Gordon to join us, and we will be delighted to take your questions. \line \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr \ltrpar \ltrrow\trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid13728027 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 19}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow
}\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt
\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
\par }}\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line 
{\*\bkmkstart 2}{\*\bkmkend 2}
\par }\pard \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs48\cf1\insrsid13728027 Question and Answer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So for folks on the phone, we're not going to be able to take any questions on the phone. So we will take them from here. Are we using microphones for the webcast? Do we have microphones? Okay, can we go to
 our first question over here to Chris Schott, please? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Christopher Thomas Schott}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 JP Morgan Chase & Co, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Chris Schott at JPMorgan. So just a higher level question to kick off, and you touched on some of this, but in light of the KE
YNOTE-189 data we saw presented today. Can you just help us understand how you see 227 and more broadly, Opdivo + Yervoy combo kind of fitting into the treatment paradigm. It seems like TMB is certainly very interesting, but your competitors are setting u
p
 a pretty high bar in more of all-comer population. And it seems like we do need some additional updates on 227 to really see where this plays in. So -- and I guess, were you thinking about kind of the potentially rapid uptake of chemo combos, were you th
i
nking about kind of PD-1 versus TMB. Just help us understand a little bit about how you see differentiating, especially given the kind of time element here as we have competitors coming to market potentially a bit sooner than you're going to have the full
 TMB picture played out? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
I think that's a question, actually, that has both a commercial and a R&D perspective. From the R&D perspective, I think what Fouad showed that is very importan
t as when you look at the 1-year survival patients who are treated with our -- with Opdivo + Yervoy high-TMB, very similar to what's been seen in other studies that were presented this morning. And again, we think that we have the potential to have a cont
i
nued, deep and durable response. You're correct that data will take some time to evolve. But at the same time, we believe that TMB testing will become more important in the market as we look at this. And again, Chris, it comes back to this point, the mark
et continues to segment, reflecting the heterogeneity in the patient population. And I do believe that there are going to be doctors and patients who will choose a chemo-sparing regimen in this setting. Murdo? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Yes, I would reinforce what Tom has already said. I see a market that will continue segment. And hearing from our thought leaders and community oncologist leaders and intend to establish mechanisms and means to know the TMB status of
 patients at time of treatment choice. And I think that's a keyword, as we've established now an opportunity for lung cancer doctors to choose optimal therapy for their patients. I think it's still fair to say that we see a PD-L1 gradient in our -- in the
 data sets that were presented today. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
And I think it's fair to say that, as Tom mentioned, there are a number of physicians who believe in the durability of Opdivo plus low dose of Yervoy from data sets they have seen in other malignancies, in melanoma
. And as Tom mentioned earlier, we secured our FDA approval today of first-line renal cell carcinoma. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So when you think about that, the prescribing population that treat lung cancer, and we're talking in the United States here, 80% of that group will 
have had some experience with Yervoy + Opdivo, either from treating melanoma patients or hopefully from treating first-line renal cell carcinoma patients. So there's going to be familiarity with that low dose Yervoy + Opdivo treatment. There's going to be
 
some movement towards establishing TMB status at point of treatment. And then I think it's up to us to make sure that the understanding of that depth and durability is there, so that choice for that patient can come into play. And then I'm sure, Tom would
 
agree there are other clinical criteria that will come into play beyond the biomarker, whether it's visceral involvement of disease, bulkiness of disease, and we see that in melanoma today. So I feel very good about us having an opportunity in first-line 
lung. And we're hopeful, obviously, that more data will come out of the 227 program to help us compare to Opdivo plus chemo versus Opdivo + Yervoy. But for now, today, I think, round one, we're in pretty good shape. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Thanks, Chris. Jami? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Jamilu E. Rubin}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Goldman Sachs Group Inc., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Just a few questions. First, just curious to know where you are with discussions with the FDA. Is this -- do you belie
ve that this combination is approvable, has the FDA signed off on the new protocol and comfortable with the data. So where are we with that in timing? Secondly, just a question that just keeps popping up and that is just Opdivo monotherapy in front-line l
u
ng. Again, while exciting to see how Yervoy is benefiting, how Yervoy is adding to the benefit of Opdivo? Opdivo alone, relative to chemo is not statistically significant, yet we've see 2 Merck trials that show KEYTRUDA, statistically significant over che
m
otherapy, so it just begs the question again. The differences between Opdivo and KEYTRUDA and why do you think that's happening? And my third question, Giovanni, is to you. So we've had 5 years now of Bristol stock has been flat despite really exciting sc
i
ence and a tremendous commitment and focus on leadership in immuno-oncology. And I'm just wondering how you're thinking about it, because the company has been outfoxed by Merck now a couple of times, and again, I think there is more information here that 
needs to be explained, probably more than you thought there would be, just given the market's reaction. So just curious what are you going to do to unlock value and put the company back in more of a leadership position? \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So I'll take -- I'll start with question one, on the FDA discussion. So Jami, as you know, we certainly are looking forward to sharing this data with the FDA. We don't comment on the nature of the discussions that we are 
having with the FDA, but we look forward to sharing this with them. We certainly have discussed the data with them when we made our statistical plan, we then finalized statistical plan, so we hope this is data that the FDA will find interesting, so we loo
k forward to that. I think Fouad asked you to discuss your thoughts about Opdivo monotherapy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Thanks, Tom, thanks, Jami. Let me just talk about the secondary endpoint, the TMB 13 that was reported today
. The cut off was prospectively defined for the combination of Opdivo + Yervoy for use in study 568. Actually for -- the cut off of 13 was an extrapolation from what we knew from our studies that was not prospectively determined like we did for the combin
a
tion so I will take that with a grain of salt. In fact, if you look at TMB 10, Opdivo has higher activity than chemotherapy and allowed us to clearly establish the contribution of components. I really think, overall, I mean, the PD-1 class of agent's perf
o
rmance within the same ballpark, and when you look at -- we focus at the first-line lung cancer because otherwise, I mean, the data with the BOR, most of the time are really very good, if not better than our agents. I think I would not compare trials to t
r
ial and apples to oranges. We got some different population, patient selection biases from one trial to another. I think the improvement we are seeing with Opdivo is very good. I would end by the other, the New England Journal Paper on new regimen Opdivo 
j
ust 2 cycles, given this impressive results in lung cancer, so clearly it is really very active and good agent. And let me just echo that, okay? You saw in The New York Times this morning that Roy Herbst said, point blank, these are Coke and Pepsi in lung
 
cancer, okay? And that reflects my belief in this as well. I believe that Opdivo, pembro are similar drugs in lung cancer. When you see differences between drugs and how they perform, almost certainly, my opinion reflects differences in trial design and p
a
tient populations. And again, I think, Fouad's point is very clear, when you look at how the different chemotherapy arms performed, they vary tremendously differently between trial. And some of those times we can figure out, many of you with issued notes 
on the different patient populations and some of those were really interesting ideas. Some we can prove, some we can't prove as you move forward. Giovanni? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 The way I think about it is the following. So 
first of all, we're a science-based company and we're all about innovation. When you think about the last 5 years, we've accomplished an extraordinary amount. Think about 15-plus indications with Opdivo. In every one of those, quite frankly, we have a lea
d
ing share and our performance is very strong. I look at the performance of our business today. We continue to execute really well commercially. I am excited about the number of short-term opportunities that we have. You saw in a slide from Tom 6 opportuni
t
ies that we have for Phase III data reads in the next 12 to 18 months. Those are all opportunities that I think are very, very significant for our oncology business. When I look at our diversification strategy, this year, we will have 3 assets outside of 
o
ncology that are going to be in advanced stage of development with TYK2, FGF21. And now we've announced we're going to take the Factor XIa program forward with Janssen. So our diversification strategy is continuing to progress. And from a capital allocati
o
n perspective, we're continuing to strengthen our pipeline through an unprecedented number of business development opportunities. So obviously, what is happening in immuno-oncology is an extraordinary transformation in the way cancer is treated, it is hap
pening very quickly. And we've been consistently saying that we just at the beginning of a long journey. I think we're better positioned than we've ever been. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Gregg? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Gregory B. Gilbert}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Deutsche Bank AG, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 It's Gregg Gilbert from DB. Tom, are you Coke or Pepsi is my first question? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 I tend to be a Coke guy, but I'm drinking a Pepsi. \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Gregory B. Gilbert}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Deutsche Bank AG, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So Murdo, what are your thoughts on the size and durability of the second line opportunity for Opdivo in light of recent data sets? And then maybe back to Tom, the TMB discussions seem t
o have pretty significant reservations about TMB from a readiness for prime time standpoint, need for additional tissue cost and essentially said it's not ready for patient care. So I assume you would take issue with that. I'd love to hear your thoughts. 
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Yes. So real quickly, Gregg, we see the shares holding up well in I-O naive second-line lung cancer. So we're still around about 30% share with Opdivo in second line. We do see some shrin
king of that population now with I-O previously experienced because of pembro monotherapy and because of the 21G cohort data that were approved. I would expect some of that erosion to accelerate given the strength of the data presented here today that the
r
e will be more I-O treatment exposure in first line going forward. That being said, I think we've seen some nice evolution in other malignancies and other tumors. So our adjuvant uptake in melanoma with Opdivo has been rapid and strong with very, very goo
d
 shares, above 40% already. We would expect that our uptake in front-line RCC for Opdivo + Yervoy, given today's approval, will also evolve. And as you know, we've got a strong share there in second line with Opdivo monotherapy. And when you look at our o
t
her shares across other malignancies, we're really fairly stable and fairly well established. So about half of our business in the U.S. is lung. Half of our business is outside of lung. And we've been able to, I think, show very strong performance despite
 some competitive pressure in front line. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 And I think on your second question regarding the TMB assays, a couple things from my perspective. And I'm going to ask Saurabh for his thought
s. The first is that we did this with an FDA approved and validated assay, which I think is very important to remember. And this is something which we believe is a valid test. I believe as a clinician that the evolution of this test will be something that
 
doctors will be able to do. Just think about it. Those of you who are clinicians, think back to the days when you ordered progesterone receptors and estrogen receptors. You guys are really young, so maybe you don't remember. It used to be a [ PIA ], and y
o
u wouldn't get it in the ER result and the PR result for 3 weeks or 4 weeks at the time, if ever. Now ER and PR are done immediately. I believe TMB will see a very similar evolution in that setting. I think to address on the specific questions, I'd like t
o introduce Saurabh Saha. Saurabh is our newly recruited head of translational medicine and someone who is leading a lot of the work at Bristol-Myers connecting the biology of cancer to new innovations. Saurabh? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Saurabh  Saha}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior VP & Global Head of Translational Medicine}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Thanks, Tom. So as Tom mentioned, we're extremely excited at BMS to be leading in a new era in precision medicine and having established TMB as a biomarker for lung cancer. I will say that the science is what we follow at BMS, a
nd hand in hand, and we are also developing the diagnostic technologies to take full advantage of that science in the development of our drugs. Now that being said, we have -- the quality of the data that we generate today matches with the diagnostic test
 
that we used in both -568 and -227 to test for TMB. And that is the FoundationOne companion diagnostic test. Now this test been FDA approved, as Tom mentioned. It also has passed analytic validation standards, which meet reproducibility, robustness and re
liability to have the performance standard that allows for this test to be clinically utilized. So we're happy to be using the Foundation test to score for TMB. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Thanks, Saurabh. Dave Risinger? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 David Reed Risinger}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Morgan Stanley, Research Division}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Dave Risinger from Morgan Stanley. I have 2 questions. First, could you just remind us, I forget what the number was in the presentation about crossover in -227, just i
n anticipation of the future OS results? And could you provide some more color on expected timing based upon the event rates for both the PD-L1 positive and TMB high groups? And then second, if you could just update us on the timing for readouts for the a
dditional segments of the -227 trial, which I guess, will be 2019, 2020, so that we have a better sense for the timing to compare to other data that we're seeing. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Fouad  Namouni}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Head of Oncology Development}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 The rate of crossover was about 30% in Ch
eckMate-227 and in this population of patients. And even in that rate of crossover, we can see a separation of the curves in the early overall survival that we shared with you. Obviously, these are patients who have tumor that are very visible to the immu
ne system and very sensitive that when they receive post-therapy PD-1 agents, they tend to respond pretty well. Still, ipilimumab is continuing to see a trend towards separation of the curve for overall survival. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
I think the second question regarding timing and readouts, I think you will be seeing some more data at ASCO. Okay, we've not disclosed exactly what the data is, but you will be seeing updates at ASCO from -227. And the key thin
g, as we said, we believe the chemotherapy immunotherapy is an important assessment that we need to do. And we'll be having data from Part 2 the study -227 as well as data from 9LA. And we believe those will probably read out in 2019. Part 2 from -227 pro
b
ably in the earlier part of 2019, and the 9LA, which as you know, incorporates 2 cycles of upfront chemotherapy followed by -- along with Opdivo-Yervoy, we believe that will read out probably later in 2019. And again, these are all event driven and you kn
ow the caveats around that, that make it slightly difficult to be much more specific than that. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 And then the PD-L1 positive is probably later this year, early next year from Ia. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Yes. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Okay, Vamil? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Vamil Kishore Divan}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Cr\'e9dit Suisse AG, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Vamil Divan, Cr\'e9
dit Suisse. Two more questions on the biomarker side. So one, appreciate the comments regarding Foundation Medicine. Can you just provide some more clarity on the partnership with Illumina and how that might change things, it was also mention
ed during the discussion around are you going to need to revalidate the results with that? Have you changed your approach? And then just with the plateau we see at the 10 mutation mark. So the 15 mutation group is actually a little bit worse but basically
 about the same. Maybe just what the rationale is why you wouldn't see more of a response when you get up to an even higher level. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 So I'll start and then asked Saurabh again. I'd say a 
couple of things. Our relationship with Illumina is important because Foundation Medicine, as you know, is a company that's based principally in the U.S. They've got some activities in the Germany that we're working with them on, and they're expanding the
i
r global reach. But as you know, we are a global company that develops our drugs for worldwide market. And in some areas, a hospital-derived kit or a clinic-derived, lab-derived kit will be an important way to go in terms of looking at TMB. And we look fo
rward to working with Illumina to be able to try to assess that. And Saurabh, you may want to address this to the question of the ROC curve and the shoulder of it. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Saurabh  Saha}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior VP & Global Head of Translational Medicine}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Sure. So I will add 
that you've seen the data on the ROC curve. What you haven't seen behind that is that we looked at the positive predictive value, the negative predictive value and the prevalence in addition to the ROC curve to determine that the cutoff ideally is between
 9 and 10 mutations per megabase. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Thanks, Vamil. Steve? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Stephen Michael Scala}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Cowen and Company, LLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Steve Scala from Cowen and Company. I h
ave one question and then 2 follow-ups. So what do you think happens to the patient who fails KEYTRUDA plus chemo in the first line? Does that patient go to another I-O therapy? Or does that patient -- is that patient lost to I-O? Murdo, when you're answe
r
ing the second line share question, I was a little confused. Were you implying the share will go up based on the strength of the -227 data or down because of the strength of the KEYNOTE-189 data? And then lastly, Dr. Lynch, this is really splitting hairs,
 
but in your response to Jami's question on the regulatory aspects, you said you look forward to sharing with the FDA, but then you said you cannot comment on discussions, implying there are discussions. So can you -- have you filed yet? Or what's going on
? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
So I'll start. So opportunity to clarify on second line. So I'll take that one, Steve. We expect our share to hold in the I-O naive pool of second-line non-small cell lung cancer patien
ts. We've been able to defend successfully, been able to hold share, but that pool of patients will decline as more of them have experienced an I-O therapy in front line. With the data that were presented today, we see an increase happening in front-line 
I
-O therapy selection. When a patient fails any I-O therapy in front line, whether that be a monotherapy PD-L1 or a combination of PD-L1 plus chemotherapy, it is very unlikely and unusual that they get retreated. I would guess in what we see in our data to
 be around 10% retreatment in second line. And I would use that number very carefully given that there's a wide range of variability from time to time when we measure it. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 I think just t
o clarify the second point, as you know, what we do is we announce when [ various ] differ from across -- in all our therapeutic areas, when filings are accepted and we have a PDUFA date, we usually announce that at that point. We don't comment on the nat
u
re of the discussions that happen beforehand. What I can tell you is that, and this is not related to -227, with all of our trials, and our competitors behave the same way, we share the data with the FDA at different times. And I'm not saying whether we'v
e
 done that yet in this setting because we don't discuss individual interactions with the FDA until we have a filing accepted and a PDUFA date. But it is -- there are a number of formal and informal interactions that comprise what I was referring to in ter
ms of sharing and discussions. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line 
}{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Andrew? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Andrew Simon Baum}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Citigroup Inc, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Andrew Baum, Citi. Three questions. So this is all referencing your c
omments about this is the beginning rather than the end of nonsmall cell. So the first one is while we may debate the competitive position of TMB high, the bulk of the market is TMB low in terms of patient population. You will have, as you outlined, the s
e
cond part of -227 reading out. What's your level of confidence that you will be able to match the magnitude of benefit that Merck illustrated today in all-comers? And particularly, related to this question, what is the time line in -227 for the part that 
y
ou've unblinded to date between enrollments in the trial and dosing with the drug? And this relates back to our theses of the impact of mandating fresh biopsies for your competitors in terms of selecting a patient group. And then second on 9LA, can you ju
s
t give us the timing of any interims as well as the stat plan? It's an all-comer trial, but -- and if you can share with us on how you think about the hierarchy will be helpful. And then finally, were you surprised by the benefit in the PD-L1 high, TMB hi
gh actually not showing benefit, and in fact, it was the PD-L1 low is the benefit to a greater degree in terms of the hazard ratio within -227? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Okay. Complex series of questions. The fi
rst, is it the beginning or the end? What justifies my thinking about it still being the beginning, as what we saw from Drew Pardoll in the end. What you saw from Drew Pardoll, as you give someone 2 cycle -- 2 doses of Opdivo and you see this unbelievable
 
response and this infiltration of CD8-positive T cells. Unbelievable. Did anyone ever imagine that, that would be enough to generate the kinds of pathological responses? That's giving us a window into understanding how these drugs are working. So I do bel
i
eve, Andrew, that it is very much at the beginning of understanding how these drugs are used. As you know, we don't disclose the statistical plans at this point. So the -- we're not going to comment on the statistical plan for Part 2 or study 9LA at this 
p
oint. We have disclosed that 9LA will collect samples for TMB. That's part of the collection in 9LA. But I also think in terms of the -- you asked about the confidence around Part 2, and I would argue Part 2 in 9LA, both being studies that we have with ch
e
motherapy, and I think that our point is that we are certainly hopeful that we'll see responses that benefit patients. And we look forward to seeing what that data is. Again, we follow the science and see where the trials lead us. We don't know yet what t
h
at's going to show, and it's very difficult to speculate on what that data could be. I believe we saw benefit in PD-L1 positive and PD-L1 negative. Well, it was encouraging to see benefits in PD-L1 negative. I think that was a place that I was very encour
a
ged by to see that there's benefit in PD-L1 negative. It certainly contributed to our overall benefit. But I think that what we will do as we gain a more experience -- and we look at interaction. The one thing we believe is that TMB and PD-L1 are compleme
n
tary biomarkers. And I think, Andrew, these are the kinds of decisions like doctors are going to make. They're look at the patient who's PD-L1 positive and TMB positive, making decision for that patient. It might be different with someone who is PD-1 nega
t
ive and TMB positive. And it might be for that patient. They think differently than for others. And I think as Murdo pointed out, it's not just biomarkers, but I think biomarkers will drive a lot of that decision making. So funny, when I look at the data 
t
his morning from Merck, they mentioned that you had to have a biopsy. It didn't mention that there was -- it was fresh. So I think one of the things we're getting at, there was some data that came out, it looks at the outcomes for patients who had -- who 
a
re in second line where biopsy for fresh tissue as opposed to people who use archived. All of -- 80% -- and Sabine will be able to comment on the exact number. A very high -- if we can give her the microphone. A very high percentage of our patients will h
a
ve biopsy within 3 months, which is really very similar to the patient population that is in the Merck trials. So whether that could have explained some of the differences on 24, 26, I think that's intriguing. In this setting, I don't really believe that 
there's going to be a huge difference. Sabine, you may want to mention what your thoughts are on the fresh. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 
Sabine Maier}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Yes, no. I totally agree with your statement. I think the vast majority of patients have a sample within 3 months. I think the o
ther thing that's really important to remember here is those are first line non-small cell lung cancer patients that typically come and they get diagnosed as metastatic or advanced non-small cell lung cancer. So this is not like in a second-line setting w
h
ere they would go through one line of treatment and then they may be some benefit in taking the additional sample. So the vast majority of patients in our trials are 80% to 90% newly diagnosed. They just had their tissue taken but at the use for the studi
es. So I don't think, looking across all those studies, that this led to any bias in terms of the patient population. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Thanks, Sabine. Geoff? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Geoffrey Christopher Meacham}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Geoff Meacham, Barclays. I just have a couple of questions. When you look at the speed of response from nivo/ipi, do you guys envision moving up the earlier patients, perhaps even pre-metastatic, even if the 
TMB may be lower? And then the second question is, both the discussions today seem to characterize TMB testing is not quite ready for prime time. So what do you guys imagine as a tipping point for broader adoption? And then last one, not related to AACR, 
but when do you think you guys will make a decision on the IDO combination trials? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 So 3 important questions there. I think the question using Opdivo + Yervoy in earlier stage disease, w
e have many trials now that are examining new adjuvant I-O. I think one of the things Drew Pardoll mentioned is that there were more than -- I think the number is 25 to 50 trials going on nationally now, looking at lung cancer and earlier stages diseases,
 either monotherapy or combination therapy. And I do think -- I eagerly look at that data because I think that, that is a place where we can make a real difference as we move forward. I think the second question was regarding TM -- can you just... \line }
{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Geoffrey Christopher Meacham}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Barclays Bank PLC, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 TMB ready for prime time? \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
TMB ready for prime time. As we've said, this is an FDA-approved and validated test. So I be
lieve strongly that the test is ready for prime time right now. In fact, Dr. Rizvi said that all patients should be treated for TMB. It's one of the summary statements in his slide today. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  
\line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Yes. I would only add on the TMB testing that a large number of academic centers already routinely ascertained TMB status of their patients. I think for the community setting, it will take either a drug approval or a guideline recommendation. But upon th
at, given that the test is FDA-approved and that the Foundation team went through the national coverage, determination process in parallel to their FDA review, reimbursability is also a fairly clear path for clinicians. So upon an approval or a guideline 
recommendation, I think, you'd see TMB testing in the community setting rise accordingly. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 I just want to clarify one thing that Tom just mentioned about the FDA approval of the test. And if Foundation -
- FDA approval of the test is not linked as a pharmaco-diagnostic to specific medicine. So obviously, we are working with Foundation to really make this an approvable test for the combination of our agents. But if they approve the test is not linked to an
y utility for any specific drug for TMB. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Important clarification that our legal team will be very excited about hearing as we announce that. Regarding, IDO, IDO, as we know, we think, i
s a target that's very interesting. In addition to working with Incyte, we also have an IDO of our own that we think may be differentiated. We have not yet -- we're looking at the data, and we have the same data that you have in terms of what's in the pub
l
ic domain regarding the study with epacadostat and pembrolizumab. And we will look at that data and make decisions about what to do with nivolumab and epacadostat. And we will interpret that data as well as some of the data that we're developing with our 
d
rug to make further decisions as we always do with drugs in our pipeline. But I think one of the key points you bring out is one of the things that we're very proud of is the optionality and depth of our pipeline. Now we haven't talked about the pipeline 
t
oday, but we have more than 22 agents now under development in lung cancer -- any cancer. And then we have more than 80 drugs in backup. So we have plenty compounds that we're looking at, and in fact, we're very proud of the partnership we announced sever
al weeks ago now with Nektar to look at developing pegylated IL2, which we think will be an interesting compound as well. So more information on IDO when it becomes available. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Any more questions? Matt? \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Matthew Christopher Phipps}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 William Blair & Company L.L.C., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Matt Phipps from William Blair. You showed PFS by all randomized patients regardless of TMB. Do you have that data if you look to that by PD-L1 expression? And does that give you confidence in the OS endpoint for the co-primary? \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Actually, we don't have that data by PD-L1 expression as it isn't hierarchy of Part 1a for the PD-1 positive. And that's even blinded to the company in terms of following the overall survival from that part. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Matthew Christopher Phipps}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 William Blair & Company L.L.C., Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
And then with the stat plan in the kind of first co-primary where you have the PFS of IDO monotherapy that you showed, does that eliminate any potential opportunity to get OS for TMB in a label since it's now kind of an observational endpoint? \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Giovanni  Caforio}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\i\f1\fs20\cf1\insrsid13728027 Chairman of the Board & CEO}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Actually, Dr. Hellmann ment
ioned very clearly this morning, this is a secondary endpoint but it's an exploratory in that in the sense it's just descriptive. Obviously, I cannot comment on the regulatory interactions and the label in this period of time, but this is descriptive and 
that is for secondary endpoint. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Jason? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Jason Matthew Gerberry}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 BofA Merrill Lynch, Research Division}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Jason Gerberry, Bank of America. Just first question for Mu
rdo. You mentioned product approvals potentially a catalyst for TMB biomarker adoption. Can you just comment how you'd envision the uptake curve of that looking relative to PD-L1 as the biomarker test? And then secondly to that, just any commentary you gu
ys can provide just in terms of how much time you think there is to improve the turnaround time on the TMB biomarker? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Sure. I think given the quality of the data that we've been able to p
resent, there is a lot of interest in Yervoy + Opdivo. So I think there's a compelling reason to understand the TMB status of patients but importantly at the time of treatment. So in the academic setting, the uptake curve is going to move relatively quick
l
y. A lot of labs have developed their own genetic panels for TMB testing. They've got well-established surgical and pathology techniques to do that. So I think that, that will be a different and more rapid uptake curve, I think, in the community will take
 
an event like an approval and a companion diagnostic, upon which I think it would rise very rapidly. And we see improvements in turnaround time routinely with the commercial test as is available right now to date. I think as that gets utilized and Foundat
i
on have more volume, they'll continue to improve on those turnaround times. Our goal, obviously, is to work with clinicians, networks, hospitals and establish reflexive testing as a standard workup for a front-line lung cancer patient. Because they get al
l
 the driver mutations in that FoundationOne assay, they get all of the gene panel information, and that allows them to make a lot of different decisions. So that's really the goal of working with Foundation. And we've got a large team of medical people de
ployed against our customers. We've got people who face the pathology audience, explaining the value of the assay. And we're tightly partnered with the Foundation group. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 Richard? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Richard Wagner}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Richard Wagner, Bernstein. A question from Tim Anderson. Given the enthusiasm that was expressed today by the panel members and all the questions that were asked and answered today, nevertheless, the market's reaction to t
he news seem to be in contrast with Bristol down 9%. So my question is, what then do you think that the market is missing in today's news? And that would be a helpful answer. Second question related to Opdivo. I know in our exchanges with investors, one o
f
 the concerning elements of the data was the PFS performance of Opdivo monotherapy in the segment of patients with the high TMB. Those were at 1%. Within that group, that would also be a segment at 50%. I think investors would feel reassured to know that 
in the high expressing group, recognizing that it's a small number of patients but nevertheless that there was some benefit with Opdivo monotherapy. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 
\ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Unknown Executive}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
Just on the market side, we're not going to comment on what the market missed or d
oes. I mean, I think it's clear that we feel good about the data that was presented advancing the science that TMB is real and it's going to be used to help select patients and that we think we have a role to play in lung cancer with a chemo sparing regim
en. How the market reacts is sort of how the market is going to react, and you're probably better positioned to tell us why the market is down than we are tell to tell you what the market missed. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
I think regarding your second question, today's presentation, as you know, is about TMB. There will be additional presentations on -227 that will look at other issues and what one of them could be potentially the super high PD-L1 patients. I thi
nk, again, to answer your first question, which is the PFS of Opdivo monotherapy, we believe it supports a contribution of components, which is very important in this setting. I think that the graph that Fouad showed very nicely showed that the benefit we
'
re seeing, we believe, is due to both Yervoy and Opdivo, which is something crucial, I think, when you're developing a combination regimen to be able to demonstrate that. And again, I come down to -- getting down to Jami's question, which is kind of impli
e
d a little bit by your question, which is the relationship between Opdivo and Pembro as single-agent drugs. And again, just to repeat, we have 15 approvals in the United States in 15 indications. We have 250 global approvals of this drug. We believe that 
t
his is an outstanding drug in cancer. And in lung cancer, in second-line lung cancer, we see equivalents between these 2 drugs in studies. And we believe we are going to have an important role in treating first-line lung cancer. I believe that the differe
n
ces that you see in first-line lung cancer in monotherapy reflect, in general, differences in the study design. Whether it's Andrew's premise of fresh versus frozen or archived, whether it's related to prior radiation use, some of you have talked about th
at, whether it's Eastern Europe versus Western Europe versus Asia, all of those factors can potentially impact. But again, that's my feeling about what we're seeing in the setting. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  
\line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 
Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
We have time for -- we have Alex over here. Him, Alex Arfaei over here. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Ardalan  Arfaei}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 BMO Capital Markets Equity Research}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 Alex Arfaei, BMO. I have 3, if I may. First, sorry if this is a silly question, but is there still a way for O
pdivo monotherapy to make it to the first-line setting? If I can, are there any important differences for the Part 2, the Opdivo plus chemo arm versus KEYNOTE 189 that we should be aware of? Is there any reason why we should expect similar benefits from t
h
at side? And then finally, I want to follow up on the low TMB question. If you look at -568, the response rate in the low-TMB patients look actually worse than chemo. I'm just wondering, to what extent you're concerned about that given that the low-TMB pa
tients would theoretically be picked up in your OS analysis? \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Thomas J. Lynch}{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Scientific Officer}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\f1\fs20\cf1\insrsid13728027 So I think just to say a couple of things about that, I think, again, when you talk about Opdivo monotherapy, I believe that
 what's happening in lung cancer is we're seeing a movement toward, in general -- I'm sorry, you're behind the podium. In general, we're seeing a movement toward a combination world. And I think you saw that in Roy Herbst's discussion today. When Roy ques
t
ioned whether even for the 50% patients, whether we'll still be using pembro mono or looking at a chemo, I-O combo. So I do think we're seeing increasingly the physicians are going to be having options with combinations. And we certainly think we are well
 
positioned in that setting. I think the question of low TMB, I think, Alex, is actually very important because I think if you have low TMB and low PD-L1, should you be getting I-O as part of your treatment option? I'm not entirely certain that you should,
 
and I think those are kind of things that we're going to need to spend more time on. And again, your question shows one of the things we've been saying for quite some time, which is that this marketplace continues to fragment. It's a heterogeneous disease
, and we believe we have -- are going to have an important role to play for many patients with non-small cell lung cancer in different settings, but well asked. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 
\af0 \ltrch\fcs0 \b\f1\fs20\cf1\insrsid13728027 Murdo  Gordon}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Former Executive VP & Chief Commercial Officer}{\rtlch\fcs1 \af0 
\ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 There's a question on Part
 2 and whether or not we see anything different. The one thing I would add to what we see in Part 2 is we'll see TMB status. And I think that's important when you look at the PD-L1 gradient and what was presented for pembro plus chemo. The low pembro -- t
he low PD-L1 expressors may have had high TMB. So we will be able to at least show the matrix of our results in Part 2. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf1\insrsid13728027 John E. Elicker}{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027  \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \i\f1\fs20\cf1\insrsid13728027 Senior Vice President of Corporate Affairs & Investor Relations}{\rtlch\fcs1 
\af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 So I think that's a little over an hour. Hopefully, 
everybody found it useful. And you have plenty of time to get to the next meeting. If you have anything you want to touch base with any of the Bristol folks, please feel free. Thanks, everybody. \line \sect }\sectd \ltrsect
\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\footerr \ltrpar \ltrrow\trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh50\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row \ltrrow}\trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\pard\plain \ltrpar
\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs14\cf21\insrsid13728027 COPYRIGHT \'a9
 2019 S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved.\cell }\pard \ltrpar\s15\qr \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 PAGE}}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 20}}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs18\cf21\insrsid13728027 \cell }\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {
\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs18\cf21\insrsid13728027 \trowd \ltrrow
\ts11\trgaph72\trrh7\trleft0\trftsWidth3\trwWidth10640\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone 
\clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth7684\clcbpatraw8 \cellx7684\clvertalt\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth2956\clcbpatraw8 \cellx10640\row \ltrrow
}\trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt\clbrdrt\brdrnone \clbrdrl
\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\pard\plain \ltrpar\s15\ql \li0\ri0\keep\widctlpar\intbl\wrapdefault\faauto\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 
\fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\field{\*\fldinst {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 HYPERLINK "http://www.marketintelligence.sglobal.com" }}{\fldrslt {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 spglobal.com/marketintelligence }}}\sectd \ltrsect\marglsxn792\margrsxn792\margtsxn792\margbsxn792\linex0\endnhere\sectdefaultcl\sftnbj {\rtlch\fcs1 \af0 \ltrch\fcs0 \b\f1\fs20\cf21\insrsid13728027 \cell 
}\pard\plain \ltrpar\ql \li0\ri0\widctlpar\intbl\wrapdefault\aspalpha\aspnum\faauto\adjustright\rin0\lin0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 
\b\f1\fs20\cf21\insrsid13728027 \trowd \lastrow \ltrrow\ts11\trgaph72\trrh200\trleft0\trftsWidth3\trwWidth5320\trpaddl72\trpaddt58\trpaddr72\trpaddfl3\trpaddft3\trpaddfb3\trpaddfr3\tbllkhdrrows\tbllkhdrcols\tbllknocolband\tblind72\tblindtype3 \clvertalt
\clbrdrt\brdrnone \clbrdrl\brdrnone \clbrdrb\brdrnone \clbrdrr\brdrnone \clcbpat8\cltxlrtb\clftsWidth3\clwWidth10640\clcbpatraw8 \cellx10640\row }\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 
\af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs20\cf1\insrsid13728027 
\par }}\pard\plain \ltrpar\s15\ql \li0\ri0\widctlpar\wrapdefault\faauto\rin0\lin0\itap0 \rtlch\fcs1 \af0\afs24\alang1025 \ltrch\fcs0 \fs24\lang1033\langfe1033\cgrid\langnp1033\langfenp1033 {\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027 Copyright 
\'a9 2019 by S&P Global Market Intelligence, a division of S&P Global Inc. All rights reserved. \line  \line  \line 
These materials have been prepared solely for information purposes based upon information generally available to the public and from sources believed to be reliable. No content (including index data, ratings
, credit-related analyses and data, research, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retri
e
val system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, (collective
l
y S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content
.
 THE CONTENT IS PROVIDED ON "AS IS" BASIS. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRO
R
S OR DEFECTS, THAT THE CONTENT'S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, c
o
mpensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even
 
if advised of the possibility of such damages. S&P Global Market Intelligence's opinions, quotes and credit-related and other analyses are statements of opinion as of the date they are expressed and not statements of fact or recommendations to purchase, h
o
ld, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence may provide index data. Direct investment in an index is not possible. Exposure to an asset class represente
d
 by an index is available through investable instruments based on that index. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitu
t
e for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where 
r
egistered as such. S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that i
s not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain nonpublic information received in connection with each analytical process. \line  \line  \line 
S&P Global may receive compensation 
for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web site
s
, www.standardandpoors.com  (free of charge), and www.ratingsdirect.com  and www.globalcreditportal.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional informatio
n about our ratings fees is available at www.standardandpoors.com/usratingsfees. \line \'a9 2019 S&P Global Market Intelligence. \line }{\rtlch\fcs1 \af0 \ltrch\fcs0 \f1\fs16\cf1\insrsid13728027 
\par }{\*\themedata 504b030414000600080000002100e9de0fbfff0000001c020000130000005b436f6e74656e745f54797065735d2e786d6cac91cb4ec3301045f748fc83e52d4a
9cb2400825e982c78ec7a27cc0c8992416c9d8b2a755fbf74cd25442a820166c2cd933f79e3be372bd1f07b5c3989ca74aaff2422b24eb1b475da5df374fd9ad
5689811a183c61a50f98f4babebc2837878049899a52a57be670674cb23d8e90721f90a4d2fa3802cb35762680fd800ecd7551dc18eb899138e3c943d7e503b6
b01d583deee5f99824e290b4ba3f364eac4a430883b3c092d4eca8f946c916422ecab927f52ea42b89a1cd59c254f919b0e85e6535d135a8de20f20b8c12c3b0
0c895fcf6720192de6bf3b9e89ecdbd6596cbcdd8eb28e7c365ecc4ec1ff1460f53fe813d3cc7f5b7f020000ffff0300504b030414000600080000002100a5d6
a7e7c0000000360100000b0000005f72656c732f2e72656c73848fcf6ac3300c87ef85bd83d17d51d2c31825762fa590432fa37d00e1287f68221bdb1bebdb4f
c7060abb0884a4eff7a93dfeae8bf9e194e720169aaa06c3e2433fcb68e1763dbf7f82c985a4a725085b787086a37bdbb55fbc50d1a33ccd311ba548b6309512
0f88d94fbc52ae4264d1c910d24a45db3462247fa791715fd71f989e19e0364cd3f51652d73760ae8fa8c9ffb3c330cc9e4fc17faf2ce545046e37944c69e462
a1a82fe353bd90a865aad41ed0b5b8f9d6fd010000ffff0300504b0304140006000800000021006b799616830000008a0000001c0000007468656d652f746865
6d652f7468656d654d616e616765722e786d6c0ccc4d0ac3201040e17da17790d93763bb284562b2cbaebbf600439c1a41c7a0d29fdbd7e5e38337cedf14d59b
4b0d592c9c070d8a65cd2e88b7f07c2ca71ba8da481cc52c6ce1c715e6e97818c9b48d13df49c873517d23d59085adb5dd20d6b52bd521ef2cdd5eb9246a3d8b
4757e8d3f729e245eb2b260a0238fd010000ffff0300504b030414000600080000002100b6f4679893070000c9200000160000007468656d652f7468656d652f
7468656d65312e786d6cec59cd8b1bc915bf07f23f347d97f5d5ad8fc1f2a24fcfda33b6b164873dd648a5eef2547789aad28cc56208de532e81c026e49085bd
ed21842cecc22eb9e48f31d8249b3f22afaa5bdd5552c99e191c3061463074977eefd5afde7bf5de53d5ddcf5e26d4bbc05c1096f6fcfa9d9aefe174ce16248d
7afeb3d9a4d2f13d2151ba4094a5b8e76fb0f03fbbf7eb5fdd454732c609f6403e1547a8e7c752ae8eaa5531876124eeb0154ee1bb25e30992f0caa3ea82a34b
d09bd06aa3566b55134452df4b51026a1f2f97648ebd9952e9dfdb2a1f53784da5500373caa74a35b6243476715e5708b11143cabd0b447b3eccb3609733fc52
fa1e4542c2173dbfa6fffceabdbb5574940b517940d6909be8bf5c2e17589c37f49c3c3a2b260d823068f50bfd1a40e53e6edc1eb7c6ad429f06a0f91c569a71
b175b61bc320c71aa0ecd1a17bd41e35eb16ded0dfdce3dc0fd5c7c26b50a63fd8c34f2643b0a285d7a00c1feee1c3417730b2f56b50866fede1dbb5fe28685b
fa3528a6243ddf43d7c25673b85d6d0159327aec8477c360d26ee4ca4b144443115d6a8a254be5a1584bd00bc6270050408a24493db959e1259a43140f112567
9c7827248a21f056286502866b8ddaa4d684ffea13e827ed5174849121ad780113b137a4f87862cec94af6fc07a0d537206f7ffef9cdeb1fdfbcfee9cd575fbd
79fdf77c6eadca923b466964cafdf2dd1ffef3cd6fbd7ffff0ed2f5fff319b7a172f4cfcbbbffdeedd3ffef93ef5b0e2d2146ffff4fdbb1fbf7ffbe7dfffebaf
5f3bb4f7393a33e1339260e13dc297de5396c0021dfcf119bf9ec42c46c494e8a791402952b338f48f656ca11f6d10450edc00db767cce21d5b880f7d72f2cc2
d398af2571687c182716f094313a60dc6985876a2ec3ccb3751ab927e76b13f714a10bd7dc43945a5e1eaf579063894be530c616cd2714a5124538c5d253dfb1
738c1dabfb8210cbaea764ce99604be97d41bc01224e93ccc899154da5d03149c02f1b1741f0b7659bd3e7de8051d7aa47f8c246c2de40d4417e86a965c6fb68
2d51e252394309350d7e8264ec2239ddf0b9891b0b099e8e3065de78818570c93ce6b05ec3e90f21cdb8dd7e4a37898de4929cbb749e20c64ce4889d0f6394ac
5cd829496313fbb938871045de13265df05366ef10f50e7e40e941773f27d872f787b3c133c8b026a53240d4376beef0e57dccacf89d6ee8126157aae9f3c44a
b17d4e9cd131584756689f604cd1255a60ec3dfbdcc160c05696cd4bd20f62c82ac7d815580f901dabea3dc5027a25d5dcece7c91322ac909de2881de073bad9
493c1b9426881fd2fc08bc6eda7c0ca52e7105c0633a3f37818f08f480102f4ea33c16a0c308ee835a9fc4c82a60ea5db8e375c32dff5d658fc1be7c61d1b8c2
be04197c6d1948eca6cc7b6d3343d49aa00c9819822ec3956e41c4727f29a28aab165b3be596f6a62ddd00dd91d5f42424fd6007b4d3fb84ffbbde073a8cb77f
f9c6b10f3e4ebfe3566c25ab6b763a8792c9f14e7f7308b7dbd50c195f904fbfa919a175fa04431dd9cf58b73dcd6d4fe3ffdff73487f6f36d2773a8dfb8ed64
7ce8306e3b99fc70e5e3743265f3027d8d3af0c80e7af4b14f72f0d46749289dca0dc527421ffc08f83db398c0a092d3279eb838055cc5f0a8ca1c4c60e1228e
b48cc799fc0d91f134462b381daafb4a492472d591f0564cc0a1911e76ea5678ba4e4ed9223becacd7d5c16656590592e5782d2cc6e1a04a66e856bb3cc02bd4
6bb6913e68dd1250b2d721614c6693683a48b4b783ca48fa58178ce620a157f65158741d2c3a4afdd6557b2c805ae115f8c1edc1cff49e1f06200242701e07cd
f942f92973f5d6bbda991fd3d3878c69450034d8db08283ddd555c0f2e4fad2e0bb52b78da2261849b4d425b46377822869fc17974aad1abd0b8aeafbba54b2d
7aca147a3e08ad9246bbf33e1637f535c8ede6069a9a9982a6de65cf6f35430899395af5fc251c1ac363b282d811ea3717a211dcbccc25cf36fc4d32cb8a0b39
4222ce0cae934e960d122231f728497abe5a7ee1069aea1ca2b9d51b90103e59725d482b9f1a3970baed64bc5ce2b934dd6e8c284b67af90e1b35ce1fc568bdf
1cac24d91adc3d8d1797de195df3a708422c6cd795011744c0dd413db3e682c0655891c8caf8db294c79da356fa3740c65e388ae62945714339967709dca0b3a
faadb081f196af190c6a98242f8467912ab0a651ad6a5a548d8cc3c1aafb6121653923699635d3ca2aaa6abab39835c3b60cecd8f26645de60b53531e434b3c2
67a97b37e576b7b96ea74f28aa0418bcb09fa3ea5ea12018d4cac92c6a8af17e1a56393b1fb56bc776811fa07695226164fdd656ed8edd8a1ae19c0e066f54f9
416e376a6168b9ed2bb5a5f5adb979b1cdce5e40f2184197bba6526857c2c92e47d0104d754f92a50dd8222f65be35e0c95b73d2f3bfac85fd60d80887955a27
1c57826650ab74c27eb3d20fc3667d1cd66ba341e31514161927f530bbb19fc00506dde4f7f67a7cefee3ed9ded1dc99b3a4caf4dd7c5513d777f7f5c6e1bb7b
8f40d2f9b2d598749bdd41abd26df627956034e854bac3d6a0326a0ddba3c9681876ba9357be77a1c141bf390c5ae34ea5551f0e2b41aba6e877ba9576d068f4
8376bf330efaaff23606569ea58fdc16605ecdebde7f010000ffff0300504b0304140006000800000021000dd1909fb60000001b010000270000007468656d65
2f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73848f4d0ac2301484f78277086f6fd3ba109126dd88d0add40384e4350d36
3f2451eced0dae2c082e8761be9969bb979dc9136332de3168aa1a083ae995719ac16db8ec8e4052164e89d93b64b060828e6f37ed1567914b284d262452282e
3198720e274a939cd08a54f980ae38a38f56e422a3a641c8bbd048f7757da0f19b017cc524bd62107bd5001996509affb3fd381a89672f1f165dfe514173d985
0528a2c6cce0239baa4c04ca5bbabac4df000000ffff0300504b01022d0014000600080000002100e9de0fbfff0000001c020000130000000000000000000000
0000000000005b436f6e74656e745f54797065735d2e786d6c504b01022d0014000600080000002100a5d6a7e7c0000000360100000b00000000000000000000
000000300100005f72656c732f2e72656c73504b01022d00140006000800000021006b799616830000008a0000001c0000000000000000000000000019020000
7468656d652f7468656d652f7468656d654d616e616765722e786d6c504b01022d0014000600080000002100b6f4679893070000c92000001600000000000000
000000000000d60200007468656d652f7468656d652f7468656d65312e786d6c504b01022d00140006000800000021000dd1909fb60000001b01000027000000
000000000000000000009d0a00007468656d652f7468656d652f5f72656c732f7468656d654d616e616765722e786d6c2e72656c73504b050600000000050005005d010000980b00000000}
{\*\colorschememapping 3c3f786d6c2076657273696f6e3d22312e302220656e636f64696e673d225554462d3822207374616e64616c6f6e653d22796573223f3e0d0a3c613a636c724d
617020786d6c6e733a613d22687474703a2f2f736368656d61732e6f70656e786d6c666f726d6174732e6f72672f64726177696e676d6c2f323030362f6d6169
6e22206267313d226c743122207478313d22646b3122206267323d226c743222207478323d22646b322220616363656e74313d22616363656e74312220616363
656e74323d22616363656e74322220616363656e74333d22616363656e74332220616363656e74343d22616363656e74342220616363656e74353d22616363656e74352220616363656e74363d22616363656e74362220686c696e6b3d22686c696e6b2220666f6c486c696e6b3d22666f6c486c696e6b222f3e}
{\*\latentstyles\lsdstimax375\lsdlockeddef0\lsdsemihiddendef0\lsdunhideuseddef0\lsdqformatdef0\lsdprioritydef0{\lsdlockedexcept \lsdqformat1 \lsdlocked0 Normal;\lsdqformat1 \lsdlocked0 heading 1;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 2;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 3;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 4;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 5;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 6;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 7;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 8;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 heading 9;\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdlocked0 caption;\lsdqformat1 \lsdlocked0 Title;
\lsdqformat1 \lsdlocked0 Subtitle;\lsdqformat1 \lsdlocked0 Strong;\lsdqformat1 \lsdlocked0 Emphasis;\lsdsemihidden1 \lsdpriority99 \lsdlocked0 Placeholder Text;\lsdqformat1 \lsdpriority1 \lsdlocked0 No Spacing;\lsdpriority60 \lsdlocked0 Light Shading;
\lsdpriority61 \lsdlocked0 Light List;\lsdpriority62 \lsdlocked0 Light Grid;\lsdpriority63 \lsdlocked0 Medium Shading 1;\lsdpriority64 \lsdlocked0 Medium Shading 2;\lsdpriority65 \lsdlocked0 Medium List 1;\lsdpriority66 \lsdlocked0 Medium List 2;
\lsdpriority67 \lsdlocked0 Medium Grid 1;\lsdpriority68 \lsdlocked0 Medium Grid 2;\lsdpriority69 \lsdlocked0 Medium Grid 3;\lsdpriority70 \lsdlocked0 Dark List;\lsdpriority71 \lsdlocked0 Colorful Shading;\lsdpriority72 \lsdlocked0 Colorful List;
\lsdpriority73 \lsdlocked0 Colorful Grid;\lsdpriority60 \lsdlocked0 Light Shading Accent 1;\lsdpriority61 \lsdlocked0 Light List Accent 1;\lsdpriority62 \lsdlocked0 Light Grid Accent 1;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 1;
\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 1;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 1;\lsdsemihidden1 \lsdpriority99 \lsdlocked0 Revision;\lsdqformat1 \lsdpriority34 \lsdlocked0 List Paragraph;
\lsdqformat1 \lsdpriority29 \lsdlocked0 Quote;\lsdqformat1 \lsdpriority30 \lsdlocked0 Intense Quote;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 1;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 1;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 1;
\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 1;\lsdpriority70 \lsdlocked0 Dark List Accent 1;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 1;\lsdpriority72 \lsdlocked0 Colorful List Accent 1;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 1;
\lsdpriority60 \lsdlocked0 Light Shading Accent 2;\lsdpriority61 \lsdlocked0 Light List Accent 2;\lsdpriority62 \lsdlocked0 Light Grid Accent 2;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 2;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 2;
\lsdpriority65 \lsdlocked0 Medium List 1 Accent 2;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 2;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 2;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 2;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 2;
\lsdpriority70 \lsdlocked0 Dark List Accent 2;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 2;\lsdpriority72 \lsdlocked0 Colorful List Accent 2;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 2;\lsdpriority60 \lsdlocked0 Light Shading Accent 3;
\lsdpriority61 \lsdlocked0 Light List Accent 3;\lsdpriority62 \lsdlocked0 Light Grid Accent 3;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 3;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 3;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 3;
\lsdpriority66 \lsdlocked0 Medium List 2 Accent 3;\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 3;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 3;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 3;\lsdpriority70 \lsdlocked0 Dark List Accent 3;
\lsdpriority71 \lsdlocked0 Colorful Shading Accent 3;\lsdpriority72 \lsdlocked0 Colorful List Accent 3;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 3;\lsdpriority60 \lsdlocked0 Light Shading Accent 4;\lsdpriority61 \lsdlocked0 Light List Accent 4;
\lsdpriority62 \lsdlocked0 Light Grid Accent 4;\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 4;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 4;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 4;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 4;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 4;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 4;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 4;\lsdpriority70 \lsdlocked0 Dark List Accent 4;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 4;
\lsdpriority72 \lsdlocked0 Colorful List Accent 4;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 4;\lsdpriority60 \lsdlocked0 Light Shading Accent 5;\lsdpriority61 \lsdlocked0 Light List Accent 5;\lsdpriority62 \lsdlocked0 Light Grid Accent 5;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 5;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 5;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 5;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 5;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 5;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 5;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 5;\lsdpriority70 \lsdlocked0 Dark List Accent 5;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 5;
\lsdpriority72 \lsdlocked0 Colorful List Accent 5;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 5;\lsdpriority60 \lsdlocked0 Light Shading Accent 6;\lsdpriority61 \lsdlocked0 Light List Accent 6;\lsdpriority62 \lsdlocked0 Light Grid Accent 6;
\lsdpriority63 \lsdlocked0 Medium Shading 1 Accent 6;\lsdpriority64 \lsdlocked0 Medium Shading 2 Accent 6;\lsdpriority65 \lsdlocked0 Medium List 1 Accent 6;\lsdpriority66 \lsdlocked0 Medium List 2 Accent 6;
\lsdpriority67 \lsdlocked0 Medium Grid 1 Accent 6;\lsdpriority68 \lsdlocked0 Medium Grid 2 Accent 6;\lsdpriority69 \lsdlocked0 Medium Grid 3 Accent 6;\lsdpriority70 \lsdlocked0 Dark List Accent 6;\lsdpriority71 \lsdlocked0 Colorful Shading Accent 6;
\lsdpriority72 \lsdlocked0 Colorful List Accent 6;\lsdpriority73 \lsdlocked0 Colorful Grid Accent 6;\lsdqformat1 \lsdpriority19 \lsdlocked0 Subtle Emphasis;\lsdqformat1 \lsdpriority21 \lsdlocked0 Intense Emphasis;
\lsdqformat1 \lsdpriority31 \lsdlocked0 Subtle Reference;\lsdqformat1 \lsdpriority32 \lsdlocked0 Intense Reference;\lsdqformat1 \lsdpriority33 \lsdlocked0 Book Title;\lsdsemihidden1 \lsdunhideused1 \lsdpriority37 \lsdlocked0 Bibliography;
\lsdsemihidden1 \lsdunhideused1 \lsdqformat1 \lsdpriority39 \lsdlocked0 TOC Heading;\lsdpriority41 \lsdlocked0 Plain Table 1;\lsdpriority42 \lsdlocked0 Plain Table 2;\lsdpriority43 \lsdlocked0 Plain Table 3;\lsdpriority44 \lsdlocked0 Plain Table 4;
\lsdpriority45 \lsdlocked0 Plain Table 5;\lsdpriority40 \lsdlocked0 Grid Table Light;\lsdpriority46 \lsdlocked0 Grid Table 1 Light;\lsdpriority47 \lsdlocked0 Grid Table 2;\lsdpriority48 \lsdlocked0 Grid Table 3;\lsdpriority49 \lsdlocked0 Grid Table 4;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 1;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 1;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 1;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 1;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 1;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 2;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 2;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 2;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 2;
\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 3;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 3;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 3;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 3;
\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 3;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 4;
\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 4;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 4;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 4;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 4;
\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 4;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 5;
\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 5;\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 5;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 5;
\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 5;\lsdpriority46 \lsdlocked0 Grid Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 Grid Table 2 Accent 6;\lsdpriority48 \lsdlocked0 Grid Table 3 Accent 6;
\lsdpriority49 \lsdlocked0 Grid Table 4 Accent 6;\lsdpriority50 \lsdlocked0 Grid Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 Grid Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 Grid Table 7 Colorful Accent 6;
\lsdpriority46 \lsdlocked0 List Table 1 Light;\lsdpriority47 \lsdlocked0 List Table 2;\lsdpriority48 \lsdlocked0 List Table 3;\lsdpriority49 \lsdlocked0 List Table 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful;\lsdpriority52 \lsdlocked0 List Table 7 Colorful;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 1;\lsdpriority47 \lsdlocked0 List Table 2 Accent 1;\lsdpriority48 \lsdlocked0 List Table 3 Accent 1;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 1;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 1;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 1;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 1;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 2;\lsdpriority47 \lsdlocked0 List Table 2 Accent 2;\lsdpriority48 \lsdlocked0 List Table 3 Accent 2;\lsdpriority49 \lsdlocked0 List Table 4 Accent 2;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 2;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 2;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 2;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 3;
\lsdpriority47 \lsdlocked0 List Table 2 Accent 3;\lsdpriority48 \lsdlocked0 List Table 3 Accent 3;\lsdpriority49 \lsdlocked0 List Table 4 Accent 3;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 3;
\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 3;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 3;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 4;\lsdpriority47 \lsdlocked0 List Table 2 Accent 4;
\lsdpriority48 \lsdlocked0 List Table 3 Accent 4;\lsdpriority49 \lsdlocked0 List Table 4 Accent 4;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 4;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 4;
\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 4;\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 5;\lsdpriority47 \lsdlocked0 List Table 2 Accent 5;\lsdpriority48 \lsdlocked0 List Table 3 Accent 5;
\lsdpriority49 \lsdlocked0 List Table 4 Accent 5;\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 5;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 5;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 5;
\lsdpriority46 \lsdlocked0 List Table 1 Light Accent 6;\lsdpriority47 \lsdlocked0 List Table 2 Accent 6;\lsdpriority48 \lsdlocked0 List Table 3 Accent 6;\lsdpriority49 \lsdlocked0 List Table 4 Accent 6;
\lsdpriority50 \lsdlocked0 List Table 5 Dark Accent 6;\lsdpriority51 \lsdlocked0 List Table 6 Colorful Accent 6;\lsdpriority52 \lsdlocked0 List Table 7 Colorful Accent 6;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Mention;
\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Smart Hyperlink;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Hashtag;\lsdsemihidden1 \lsdunhideused1 \lsdpriority99 \lsdlocked0 Unresolved Mention;}}{\*\datastore }}